WO1997027559A1 - Method of creating and searching a molecular virtual library using validated molecular structure descriptors - Google Patents
Method of creating and searching a molecular virtual library using validated molecular structure descriptors Download PDFInfo
- Publication number
- WO1997027559A1 WO1997027559A1 PCT/US1997/001491 US9701491W WO9727559A1 WO 1997027559 A1 WO1997027559 A1 WO 1997027559A1 US 9701491 W US9701491 W US 9701491W WO 9727559 A1 WO9727559 A1 WO 9727559A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecules
- molecule
- descriptor
- structural
- product
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 344
- 150000001875 compounds Chemical class 0.000 claims abstract description 223
- 239000000376 reactant Substances 0.000 claims description 327
- 238000012216 screening Methods 0.000 claims description 154
- 230000000694 effects Effects 0.000 claims description 123
- 238000003786 synthesis reaction Methods 0.000 claims description 97
- 238000006243 chemical reaction Methods 0.000 claims description 68
- 239000000126 substance Substances 0.000 claims description 59
- 230000015572 biosynthetic process Effects 0.000 claims description 58
- 230000008569 process Effects 0.000 claims description 47
- 239000012634 fragment Substances 0.000 claims description 43
- 238000006258 combinatorial reaction Methods 0.000 claims description 37
- 238000010200 validation analysis Methods 0.000 claims description 34
- 150000002611 lead compounds Chemical class 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 238000003556 assay Methods 0.000 claims description 20
- 238000012512 characterization method Methods 0.000 claims description 16
- 238000006062 fragmentation reaction Methods 0.000 claims description 16
- 238000013467 fragmentation Methods 0.000 claims description 15
- 230000000712 assembly Effects 0.000 claims description 11
- 238000000429 assembly Methods 0.000 claims description 11
- 239000012528 membrane Substances 0.000 claims description 8
- 231100000331 toxic Toxicity 0.000 claims description 7
- 230000002588 toxic effect Effects 0.000 claims description 7
- 125000003636 chemical group Chemical group 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 150000002739 metals Chemical class 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 238000004880 explosion Methods 0.000 claims description 4
- 238000007423 screening assay Methods 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 10
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 8
- 230000002452 interceptive effect Effects 0.000 claims 5
- 238000006757 chemical reactions by type Methods 0.000 claims 4
- 241000269627 Amphiuma means Species 0.000 claims 2
- 239000000047 product Substances 0.000 description 228
- 125000004429 atom Chemical group 0.000 description 110
- 230000004071 biological effect Effects 0.000 description 55
- 238000013461 design Methods 0.000 description 48
- 239000003153 chemical reaction reagent Substances 0.000 description 44
- 238000002898 library design Methods 0.000 description 38
- 238000013459 approach Methods 0.000 description 37
- 238000004458 analytical method Methods 0.000 description 34
- 102000005962 receptors Human genes 0.000 description 28
- 108020003175 receptors Proteins 0.000 description 28
- 238000010276 construction Methods 0.000 description 25
- 238000005070 sampling Methods 0.000 description 25
- 239000000523 sample Substances 0.000 description 21
- 238000005457 optimization Methods 0.000 description 19
- 239000011159 matrix material Substances 0.000 description 17
- 230000008901 benefit Effects 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000004364 calculation method Methods 0.000 description 11
- 125000004122 cyclic group Chemical group 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 238000004617 QSAR study Methods 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 238000012938 design process Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000007876 drug discovery Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 150000004985 diamines Chemical class 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 5
- 230000009141 biological interaction Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- QJHCNBWLPSXHBL-UHFFFAOYSA-N cimetidine hydrochloride Chemical compound [H+].[Cl-].N#C/N=C(/NC)NCCSCC=1N=CNC=1C QJHCNBWLPSXHBL-UHFFFAOYSA-N 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 229940106721 tagamet Drugs 0.000 description 5
- 229940108322 zantac Drugs 0.000 description 5
- 125000002015 acyclic group Chemical group 0.000 description 4
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000005686 electrostatic field Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- -1 if desired Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 238000013479 data entry Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000009795 derivation Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009510 drug design Methods 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 238000003032 molecular docking Methods 0.000 description 3
- 238000006053 organic reaction Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- HGYZMIFKJIVTLJ-UHFFFAOYSA-N 4-chloro-2,3-dihydro-1h-pyrrolo[3,2-c]pyridine Chemical compound ClC1=NC=CC2=C1CCN2 HGYZMIFKJIVTLJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000533950 Leucojum Species 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008236 biological pathway Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008570 general process Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 238000011524 similarity measure Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000003419 tautomerization reaction Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 244000026610 Cynodon dactylon var. affinis Species 0.000 description 1
- 241001050985 Disco Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Chemical group 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 238000011525 Tanimoto similarity measure Methods 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- BBLQPTPVRXCOFD-UHFFFAOYSA-N [Br].CCBr Chemical compound [Br].CCBr BBLQPTPVRXCOFD-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000007519 figuring Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/62—Design of libraries
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/60—In silico combinatorial chemistry
- G16C20/64—Screening of libraries
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/0068—Means for controlling the apparatus of the process
- B01J2219/007—Simulation or vitual synthesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S707/00—Data processing: database and file management or data structures
- Y10S707/99941—Database schema or data structure
- Y10S707/99943—Generating database or data structure, e.g. via user interface
Definitions
- This invention relates to the field of molecular structure/activity analysis and more specifically to: 1) a method of validating molecular structural descriptors; 2) a method using validated molecular descriptors to design an optimally diverse combinatorial screening library; 3) a method of merging libraries derived from different combinatorial chemistries; 4) a method using validated molecular descriptors of generating a searchable virtual library of molecules which can be combinatorially derived; 5) methods of searching the virtual library for combinatorially derived product molecules which meet specified criteria; and 6) methods of following up and optimizing identified leads.
- the screening libraries designed by the methods of this invention are constructed to ensure that an optimal structural diversity of compounds is represented.
- the search methods of the invention ensure that the same diversity space is not oversampled and that compounds can be identified having a high likelihood of possessing the same structure and/or activity of a lead compound.
- the invention describes the design of libraries of small molecules to be used for pharmacological testing.
- Combinatorial libraries are collections of molecules generated by synthetic pathways in which either: 1) two groups of reactants are combined to form products; or 2) one or more positions on core molecules are substituted by a different chemical constituent/moiety selected from a large number of possible constituents.
- the first idea common to all drug research, is that somewhere amongst the diversity of all possible chemical structures there exist molecules which have the appropriate shape and binding properties to interact with any biological system.
- the second idea is the belief that synthesizing and testing many molecules in parallel is a more efficient way (in terms of time and cost) to find a molecule possessing a desired activity than the random testing of compounds, no matter what their source.
- any screening library subset of some universe of combinatorially accessible compounds there are two criteria which must be met by any screening library subset of some universe of combinatorially accessible compounds.
- the diversity the dissimilarity of the universe of compounds accessible by some combinatorial reaction, must be retained in the screening subset.
- a subset which does not contain examples of the total range of diversity in such a universe would potentially miss critical molecules, thereby frustrating the very reason for the creation of the subset.
- the ideal subset should not contain more than one compound representative of each aspect of the diversity of the larger group. If more than one example were included, the same diversity would be tested more than once. Such redundant screening would yield no new information while simultaneously increasing the number of compounds which must be synthesized and screened.
- the fundamental problem is how to reduce to a manageable number the number of compounds that need to be synthesized and tested while at the same time providing a reasonably high probability that no possible molecule of biological importance is overlooked.
- a conceptual analogy to the problem might be: what kind of filter can be constructed to sort out from the middle of a blinding snowstorm individual snowflakes which represent all the classes of crystal structures which snowflakes can form?
- a combinatorial screening library For design of a screening subset of a combinatorial library (hereafter referred to as a "combinatorial screening library"), it should only be necessary to identify which molecules are structurally similar and which structurally dissimilar. According to the selection criteria outlined above, one molecule of each structurally similar group in the combinatorially accessible chemical universe would be included in the library subset. Such a library would be an optimally diverse combinatorial screening library.
- the problem for medicinal chemists is to determine how the intuitively perceived notions of structural similarity of chemical compounds can be validly quantified. Once this question is satisfactorily answered, it should be possible to rationally design combinatorial screening libraries.
- the difficulty is to find a useful design space - a quantifiable dimensional space (metric space) in which compounds with similar biological properties cluster; ie. , are found measurably near to each other.
- a molecular structural descriptor which, when applied to the molecules of the chemical universe, defines a dimensional space in which the "nearness" of the molecules with respect to a specified characteristic (ie.; biological activity) in the chemical universe is preserved in the dimensional space.
- a molecular structural descriptor (metric) which does not have this property is useless as a descriptor of molecular diversity.
- a valid descriptor is defined as one which has this property.
- the typical prior art approach for establishing selection criteria for screening library subsets relied on the following clustering paradigm: 1) characterization of compounds according to a chosen descriptor(s) (metric[s]); 2) calculation of similarities or "distances" in the descriptor (metric) between all pairs of compounds; and 3) grouping or clustering of the compounds based on the descriptor distances.
- the idea behind the paradigm is that, within a cluster, compounds should have similar activities and, therefore, only one or a few compounds from each cluster, which will be representative of that cluster, need be included in a library. The actual clustering is done until the prior art user feels comfortable with the groupings and their spacing.
- Martin et al. 4 have characterized the varieties of shape that an unknown receptor cavity might assume by a few assemblages of blocks, called "polyominos". Candidates for a combinatorial design are classified by the types of polyominos into which they can be made to fit, or "docked”. The 7 flexible polyomino shape descriptors are added to the previously defined 16 descriptors to yield a 23 dimensional property space. Martin has demonstrated that the docking procedure generates for a methotrexate ligand in a cavity of dihydrofolate reductase nearly the correct structure as that established by X-ray diffraction studies.
- D. Chapman et al. 7 have used their "Compass" 3D-QSAR descriptor which is based on the three dimensional shape of molecules, the locations of polar functionalities on the molecules, and the fixation entropies of the molecules to estimate the similarity of molecules. Essentially, using the descriptor, they try to find the molecules which have the maximum overlap (in geometric/cartesian space) with each other. The shape of each molecule of a series is allowed to translate and rotate relative to each other molecule and the internal degrees of freedom are also allowed to rotate in an iterative procedure until the shapes with greatest or least overlap similarity are identified.
- Another related problem in the prior art is the failure to have any objective manner of ascertaining when the library subset under design has an adequate number of members; that is, when to stop sampling.
- the distribution of the diversity of molecules one arbitrary stopping point is as good as any other. Any stopping point may or may not sample sufficiently or may oversample.
- the prior art has not recognized a coherent quantitative methodology for determining the end point of selection.
- a metric is used to maximize the presumed differences between molecules (typically in a clustering analysis), and a very large number of molecules are chosen for inclusion in a screening library subset based on the belief that there is safety in numbers; that sampling more molecules will result in sampling more of the diversity of a combinatorially accessible chemical space.
- a metric is used to maximize the presumed differences between molecules (typically in a clustering analysis), and a very large number of molecules are chosen for inclusion in a screening library subset based on the belief that there is safety in numbers; that sampling more molecules will result in sampling more of the diversity of a combinatorially accessible chemical space.
- only by including all possible molecules in a library will one guarantee that all of the diversity has been sampled. Short of such total sampling, users of prior art library subsets constructed along the lines noted above do not know whether a random sample, a representative sample, or a highly skewed sample has been screened.
- Another major problem with the inclusion of multiple and potentially non-diverse compounds in the same screening mixture is that many assays will yield false positives (have an activity detected above a certain established threshold) due to the combined effect of all the molecules in the screening mixture.
- the absence of the desired activity is only determined after expending the time, effort, and expense of identifying the molecules present in the mixture and testing them individually.
- Such instances of combined reactivity are reduced when the screening mixture can be selected from molecules belonging to diverse groups of an optimally designed library since it is not as likely that molecules of different (diversity) structures would likely produce a combined effect.
- the first aspect of the present invention is the discovery of a generalized method of validating descriptors of molecular structural diversity. The method does not assume any prior knowledge of either the nature of the descriptor or of the biological system being studied and is generally applicable to all types of descriptors of molecular structure. This discovery enables several related advances to the art.
- the second aspect of the invention is the discovery of a method of generating a validated three dimensional molecular structural descriptor using CoMFA fields. To generate these field descriptors required solving the alignment problem associated with these measurements. The alignment problem was solved using a topomeric procedure.
- a third aspect of the invention is the discovery that validated molecular structural descriptors applicable to whole molecules can be used both to: 1) quantitatively define a meaningful end-point for selection in defining a single screening library (sampling procedure); and 2) merge libraries so as not to include molecules of the same or similar diversity. It is shown that a known metric (Tanimoto 2D fingerprint similarity) can be used in conjunction with the sampling procedure for this purpose.
- a fourth aspect of the invention is the discovery of a method of using validated reactant and whole molecule molecular structural descriptors to rationally design a combinatorial screening library of optimal diversity. In particular, the shape sensitive topomeric CoMFA descriptor and the atom group Tanimoto 2D similarity descriptor may be used in the library design. As a benefit of designing a combinatorial screening library of optimal diversity based on validated molecular descriptors, many prior art problems associated with the synthesis, identification, and screening of mixtures of combinatorial molecules can be reduced or eliminated.
- a fifth aspect of the invention is the use of validated molecular structural descriptors to guide the search for optimally active compounds after a lead compound has been identified by screening.
- a screening library designed for optimal diversity using validated descriptors
- validated descriptors provide a method for identifying the molecular structural space nearest the lead which is most likely to contain compounds with the same or similar activity.
- a sixth aspect of this invention is the discovery of a method for generating, using validated molecular descriptors, a virtual library of product molecules derivable from combinatorial reactions (or which may be represented by a combinatorial SLN [CSLN]) in which the characteristics of product molecules can be searched and compared without the actual construction of the product molecules.
- This virtual library allows the searching of billions of possible product molecules in reasonable amounts of time.
- a seventh aspect of this invention is the discovery that, using validated molecular descriptors, the virtual library can be searched over billions of possible product molecules in ways to yield both optimally diverse screening libraries and to follow up on lead explosions.
- An eighth aspect of this invention is the discovery of a way to search, using validated molecular descriptors, the virtual library for possible molecules which have similar structures and/or activities to a query molecule which is not necessarily derived from a combinatorial synthesis. This discovery opens up a whole new method for seeking molecules with similar characteristics to a previously identified molecule.
- topomeric alignments may be used to describe molecular conformations.
- Tanimoto 2D similarity molecular structural descriptor as a product descriptor in the design of an optimally diverse combinatorial screening library.
- Figure 1 schematically shows the distribution of molecular structures around and about an island of biological activity in a hypothetical two dimensional metric space for a poorly designed prior art library and for an efficiently designed optimally diverse screening library.
- Figure 2 shows a theoretical scatter plot (Patterson Plot) for a metric having the neighborhood property in which the X axis shows distances in some metric space calculated as the absolute value of the pairwise differences in some candidate molecular descriptor and the Y axis shows the absolute value of the pairwise differences in biological activity.
- Figure 3 shows a Patterson plot for an illustrative data set.
- Figure 4 shows a Patterson plot for the same data set as in Figure 3 but where the diversity descriptor values (X axis) associated with each molecule have been replaced by random numbers.
- Figure 5 shows a Patterson plot for the same data set as in Figure 3 but where the diversity descriptor values (X axis) associated with each molecule have been replaced by a normalized force field strain energy/atom value.
- Figure 6 shows three molecular structures numbered and marked in accordance with the topomeric alignment rule.
- Figure 7 is a complete set of Patterson plots for the twenty data sets used for the validation studies of the topomeric CoMFA descriptor.
- Figure 8 shows the two scatter plots displaying the relation between X 2 values and their corresponding density ratio values for the tested metrics over the twenty random data sets.
- Figure 9 shows the graphs of the Tanimoto similarity measure vs. the pairwise frequency of active molecules for 18 groups examined from Index Chemicus.
- Figure 10 shows a Patterson plot of the Cristalli data set using only those values which would have been used for a Tanimoto sigmoid plot of the same data set alongside a Patterson plot of the complete data set.
- Figure 11 is a schematic of the combinatorial screening library design process.
- Figure 12 shows a comparison of the volumes of space occupied by different molecules which are determined to be similar according to the Tanimoto 2D fingerprint descriptor but which are determined to be dissimilar according to the topomeric CoMFA field descriptor.
- Figure 13 shows a plot of the Tanimoto 2D pairwise similarities for a typical combinatorial product universe.
- Figure 14 shows the distribution of molecules resulting from a combinatorial screening library design plotted according to their Tanimoto 2D pairwise similarity after reactant filtering and after final product selection.
- Figure 15 shows the distribution of molecules plotted according to their Tanimoto 2D pairwise similarity of three database libraries (Chapman & Hall) from the prior art.
- Figure 16 shows a schematic representation of sets of possible reactants attached to a central core.
- Figure 17 is a flowchart summarizing the overall process of virtual library construction.
- Figures 18, 19, and 20 are a flowchart summarizing the overall process of applying the Tanimoto fingerprint metric for use in the virtual library.
- Figures 21, 22, and 23 are a flowchart summarizing the overall process of using the Tanimoto fingerprint metric to search for molecules.
- Figures 24, 25, and 26 are a flowchart summarizing the overall process of using both the topomeric CoMFA and Tanimoto metrics to search for molecules in the virtual library.
- Figures 27, 28, 29, and 30 are a flowchart summarizing the overall process for topomeric searches of arbitrary query molecules.
- Figure 31 shows the topomeric conformations of Tagamet and Zantac. Disclosure Of Invention
- 2D MEASURES shall mean a molecular representation which does not include any terms which specifically incorporate information about the three dimensional features of the molecule.
- 2D is a misnomer used in the art and does not mean a geometric "two dimensional" descriptor such as a flat image on a piece of paper. Rather, 2D descriptors take no account of geometric features of a molecule but instead reflect only the properties which are derivable from its topology; that is, the network of atoms connected by bonds.
- 2D FINGERPRINTS shall mean a 2D molecular measure in which a bit in a data string is set corresponding to the occurrence of a given 2-7 atom fragment in that molecule.
- strings of roughly 900 to 2400 bits are used.
- a particular bit may be set by many different fragments.
- COMBINATORIAL SCREENING LIBRARY shall mean a subset of molecules selected from a combinatorial accessible universe of molecules to be used for screening in an assay.
- MOLECULAR STRUCTURAL DESCRIPTOR shall mean a quantitative representation of the physical and chemical properties determinative of the activity of a molecule.
- METRIC is synonymous with MOLECULAR STRUCTURAL DESCRIPTOR and is used interchangeably throughout this Application.
- PATTERSON PLOTS shall mean two dimensional scatter plots in which the distance between molecules in some metric is plotted on the X axis and the absolute difference in some biological activity for the same molecules is plotted on the Y axis.
- SIGMOID PLOTS shall mean two dimensional plots for which the proportion of molecular pairs in which the second molecule is also active is plotted on the Y axis and the pairwise Tanimoto similarity is plotted in intervals on the X axis.
- TOPOMERIC ALIGNMENT shall mean conformer alignment based on a set of alignment rules.
- the similarity principle suggests a way to quantify the concept of diversity by quantifying structural similarity. While the prior art devised many structural descriptors, no one has been able to explicitly show that any of the descriptors are valid. It is possible with the method of this invention to determine the validity of any metric by applying it to presently existing literature data sets, for which values of biological activity and molecular structure are known. Once the validity has been determined, the metric may be used with confidence in designing combinatorial screening libraries and in following up on discovered leads. Examples of these applications will be given below.
- the present invention is the first to recognize that the similarity principle also provides a way to validate metrics.
- the similarity principle requires that any valid descriptor must have a "neighborhood property". That is: the descriptor must meet the similarity principle's constraint that it measure the chemical universe in such a way that similar structures (as defined by the descriptor) have substantially similar biological properties. Or stated slightly differently: within some radius in descriptor space of any given molecule possessing some biological property, there should be a high probability that other molecules found within that radius will also have the same biological property. If a descriptor does not have the neighborhood property, it does not meet the similarity principle, and can not be valid. Regardless of the computations involved or the intentions of the users, using prior art descriptors without the neighborhood property results, at best, in random selection of compounds to include in screening libraries.
- Figure 1A and Figure 1B show an "island" 1 of biological activity plotted in some relevant two dimensional molecular descriptor space.
- the molecules 2 of a typical prior art library are plotted as hexagons.
- a circle 3 describes the area of the metric space (the neighborhood) in which molecules of similar structural diversity to the plotted molecule would be found. Since the prior art metric used to select these molecules was not valid, the molecules are essentially distributed at random in the metric space.
- the circles 3 (neighborhoods) of similar structural diversity of several of the molecules overlap at 4 indicating that they sample the same diversity space.
- the island area will be adequately sampled or that a great deal of redundant testing will not be involved with such a library design.
- Figure 1B the molecules 5 of a optimally designed library are plotted as stars along with their corresponding circles 3 of similar structural diversity. Since a valid molecular descriptor with the neighborhood property was used to select the molecules, molecules were identified which not only sampled that part of the descriptor space accessible with the molecular structures available but also did not sample the same descriptor space more than once. Clearly, the likelihood of sampling the "island" 1 is greater when it is possible to identify the unique neighborhood 3 around each sample molecule and choose molecules that sample different areas. Figure 1B represents an optimally diverse design.
- the absolute differences in the metric values for each pair of molecules are the independent variables and the absolute differences in biological activity for each pair of molecules are the dependent variables.
- the absolute value is used since it is the difference, not its sign, which is important.
- Line 1 on the graph of Figure 2 depicts a special case where there is a strictly linear relationship between differences in metric distance and differences in biological activity.
- the neighborhood property does not imply a linear correlation (corresponding to points lying on a straight line) and need not imply anything about large property differences causing large biological activity differences.
- the line should be linear for only very small changes in molecular structure and would exhibit a complex shape overall depending on the nature of the biological interaction.
- the slope of line 1 will vary depending on the biological activity of the measured system.
- the lower right trapezoid (LRT) ⁇ defined by the vertices [0,0], [actual metric value, max. bio. value], [max. metric value, max. bio. value], and [max. metric value, 0] ⁇ of the plot may be populated as shown in any number of ways.
- the upper left triangle (ULT) of the plot (above the line) should not be populated at all as long as the descriptor completely characterizes the compound and there are no discontinuities in the behavior of the molecules.
- some population of the space (as indicated by points 2) above the line would be expected since there are known discontinuities in the behavior of real molecular ligands.
- Figure 3 shows a Patterson plot of a real world example. Points lying above the solid line near the Y axis reflect a metric space where a small difference in metric property (structure) produces a large difference in biological property. These points clearly violate the similarity principle/neighborhood rule. Thus, in the real world sometimes relatively small differences in structure can produce large differences in activity. If some points lie above the line, the metric is less ideal, but, clearly still useful. The major criteria and the key point to recognize is that for a metric to be valid the upper left triangle will be substantially less populated than the lower right trapezoid.
- any (metric) descriptor displaying the above characteristic of predominantly populating the lower right trapezoid (such as in Figure 3) will possess the neighborhood property, and the demonstration that a metric possesses such behavior indicates the validity/usefulness of that metric.
- a descriptor in which the points in the difference plot are uniformly distributed (equal density of points in ULT and LRT) does not obey the neighborhood principle and is invalid as a metric. While a brief glance at the difference plots may quickly indicate validity or non-validity, visual analysis may be misleading.
- the triangle is defined by the points [0, 0], [actual metric value, max. bio. value], and [0, max. bio. value].
- the trapezoid is defined by the points [0,0], [actual metric value, max. bio. value], [max. metric value, max. bio. value], and [max. metric value, 0].
- the density of points in the lower right trapezoid should be significantly greater than the density in the upper left triangle.
- the line must always pass through (0,0) at the lower left corner of a Patterson plot since no change in any metric must imply no change in the biological activity.
- a "perfect" metric which totally describes the structure activity relationship of the biological system, would display a complex line reflecting the biological interaction.
- a "useful" straight line can be found which meaningfully reflects the variation in the density of points.
- the preferred search for the correct/useful line tests only those slopes which a particular data set can distinguish; specifically those drawn from [0,0] to each point [actual metric value, max bio value].
- the process starts by drawing the line to a point having the smallest actual metric value [smallest metric value, max. bio. value] and continues for all of the values observed for actual metric value up to the largest [largest metric value, max. bio. value]; ie, subsequent lines are of decreasing slope. (In the limiting case of drawing the line to [largest metric value, max. bio.
- the trapezoid becomes a triangle.
- it is defined to be the one which yields the highest density (number of data points/unit graph area) for a lower right triangle, which for this process is defined to have its vertices at [0, 0], [actual metric value, 0], and [actual metric value, max bio. value].
- the line is identified based on the density of points under this triangle, but the evaluation ratios for the metric are calculated based on the density within the trapezoid compared to the density of the entire plot (sum of triangle and trapezoid areas).
- the software necessary to implement this procedure is contained in Appendix "A”.
- the ratio of the density of points in the lower right trapezoid to the average density of points is determined. This value can vary from somewhere above 0 but significantly less than 1 , through 1 (equal density of points in each area) to a maximum of 2 (all the points in the lower right trapezoid, and the upper triangle and lower trapezoid are equal in area [limiting case of trapezoid merging into triangle]). According to the theoretical considerations discussed above, a ratio very near or equal to 1 (approximately equal densities) would indicate an invalid metric, while a ratio (significantly) greater than 1 would indicate a valid metric.
- the statistical significance of the Patterson plot data can also be determined by a chisquared test at any chosen level of significance.
- the data are handled as:
- the chi-squared values for the Patterson plots of Figures 3, 4, and 5 are also set forth next to the plots under the column X 2
- the chi-squared value is 3.84.
- the chi-squared values confirm the visual inspection and density ratio observations that the CoMFA metric is valid and the other two "constructed" metrics are invalid.
- a full set of topomeric CoMFA, random number, and force field data are discussed below under validation of the topomeric CoMFA descriptor.
- the analysis of metrics using the difference plot of this invention is a powerful tool with which to examine metrics and data sets.
- the analysis can be used with any system and requires no prior assumptions about the range of activities or structures which need to be considered.
- the plot extracts all the information available from a given data set since pairwise differences between all molecules are used.
- the prior art believed that not much information, if any, could be extracted from literature data sets since, generally, there is not a great deal of structural variety in each set.
- a metric can be validated based on just such a limited data set.
- metrics can be applied to literature data sets to determine the validity of the metrics.
- Two molecules of identical structure will have substantially different molecular interaction energies if they are translated or rotated so as to move their atoms more than about 4 A from their original positions.
- alignment is hard enough when applying CoMFA to analyze a set of molecules which interact with the same biological receptor.
- the more difficult question is how to "align" molecules distributed in multidimensional chemistry space to create a meaningful descriptor with respect to arbitrary and unknown receptors against which the molecules will ultimately be tested.
- the topomeric alignment procedure was developed to correct the usual CoMFA alignments which often overemphasize a search for "receptor-bound", “minimum energy”, or "field-fit" conformations.
- CoMFA modeler seeks low energy conformations.
- alignment with unknown receptors such as is the case in designing combinatorial screening libraries for general purpose screening
- the major goal in conformer generation must be that molecules having similar topologies should produce similar fields.
- topomeric CoMFA fields may be used as a validated diversity descriptor to identify molecules with similar or dissimilar structures anytime there is a problem of having more compounds than can be easily dealt with.
- the topomeric alignment procedure is especially applicable to the design of a combinatorial screening library.
- topomeric conformer is that it is rule based. The exact rules may be modified for specific circumstances. In fact, once it is appreciated from the teaching of this invention that a particular topomeric protocol is useful (yields a valid molecular descriptor), other such protocols may be designed and their use is considered within the teaching of this disclosure. i. General Topomeric Alignment
- topologically-based rules will generate a single, consistent, unambiguous, aligned topomeric conformation for any molecule.
- the software necessary to implement this procedure is contained in Appendix "A".
- the starting point for a topomeric alignment of a molecule is a CONCORD generated three dimensional model which is then FIT as a rigid body onto a template 3D model by least-squares minimization of the distances between structurally corresponding atoms.
- the template model is originally oriented so that one of its atoms is at the Cartesian origin, a second lies along the X axis, and a third lies in the XY plane.
- Torsions are then adjusted for all bonds which: 1) are single and acyclic; 2) connect polyvalent atoms; and 3) do not connect atoms that are polyvalent within the template model structure since adjusting such bonds would change the template- matching geometry.
- Unambiguous specification of a torsion angle about a bond also requires a direction along that bond and two attached atoms. In this situation, for acyclic bonds the direction "away from the FIT atoms" is always well-defined.
- the following precedence rules determine the two attached atoms. From each candidate atom, begin growing a "path", atom layer by atom layer, including all branches but ending whenever another path is encountered (occurrence of ring closure). At the end of the bond that is closer to the FIT atoms, choose the attached atom beginning the shortest path to any FIT atom. If there are several ways to choose the atom, first choose the atom with the lowest X. If there are still several ways to choose the atom, choose next the atom with the lowest Y, and finally, if necessary, the lowest Z coordinate (coordinate values differing by some small value, typically less than 0.1 Angstroms, are considered as identical). At the other end of the bond, choose the atom beginning the path that contains any ring.
- atoms attached to each of the bonded atoms must also be specified. For example, setting torsion about the bond 5 - 8 to 60 degrees would yield four different conformers depending on whether it is the 6-5-8-13, 6-5-8-9, 4-5-8-9, or 4-5-8-13 dihedral angle which becomes 60 degrees.
- "paths" are grown from each of the candidate atoms, in "layers", each layer consisting of all previously unvisited atoms attached to any existing atom in any path.
- Figure 6(B) shows the four paths after the first layer of each is grown
- Figure 6(C) shows the final paths.
- torsion 4-5-8-9 is set to 60 degrees, because both the 4-5 and 8-9 bonds are within a ring; torsions 9-10-14-15 and attached -1-3-4 become 90°, because only the 3-4 and 9-10 bonds respectively are cyclic; and the attached -1-2-16 dihedral becomes 180° since none of the bonds are cyclic. It should be noted that this topomeric alignment procedure will not work with molecules containing chiral centers since, for each chiral center, two possible three dimensional configurations are possible for the same molecule, and, clearly, each configuration by the above rules would yield a different topomeric conformer.
- Figure 6(D) shows a side chain whose attachment atom is marked as "Root” and in which atom I is chiral. Atom I has four non-equivalent attachments, indicated by Root, J, K, and L. Although the absolute configuration of such a chiral atom is not usually specified, an allingment methodology of an explicit 3D model must necessarily consistently select one of the two possible conformations, even if arbitrarily chosen.
- the reative position of atoms K and L must be exchanged To exchange the positions of atoms K and L, generate the plane defined by the second (Root) through fourth (J) atoms on the torsion that was initially set. Finally, reflect the coordinates of all the atoms attached to the third atom (I) through that plane. This topomeric procedure will generate a consistent topomeric allignment for all side chains containing chiral centers.
- a second specialized topomeric allignment problem which may be encontered is the requirement to select between two equivalent atoms. This situation is also illustrated in Figure 6(D) where there are two candidate attachment atoms, "A” and “a”, for the torsion A(a)-B-C-D. Topologically atoms "A” and “a” are identical, but a different position for the five-membered ring, hence a very different shape, will be generated depending on whether “A” or "a” is used to assign the torsion of A(a)-B-C-D. The following rule is used to ensure that the choice between "A” and "a” is made consistently.
- the critical point is that the use of a single topomerically aligned conformer in computing a CoMFA three dimensional descriptor has been found to yield a validated descriptor. While other approaches to conformer selection such as averaging many representative conformers or classifying a representative set by their possible interactions with a theoretically averaged receptor (such as in the polyomino docking) are possible, it has been found that topomerically aligned conformers yield a validated descriptor which, as will be seen below, produces clustering highly consistent with the accumulated wisdom of medicinal chemistry.
- the basic CoMFA methodology provides for the calculaiion of both steric and electrostatic fields. It has been found up to the present point in time that using only the steric fields yields a better diversity descriptor than a combination of steric and electrostatic fields. There appear to be three factors responsible for this observation. First is the fact that steric interactions - classical bioisosterism - are certainly the best defined and probably the most important of the selective non-covalent interactions responsible for biological activity. Second, adding the electrostatic interaction energies may not add much more information since the differences in electrostatic fields are not independent of the differences in steric fields. Third, the addition of the electrostatic fields will halve the contribution of the steric field to the differences between one shape and another.
- the steric fields of the topomerically aligned molecular side chain reactants are generated almost exactly as in a standard CoMFA analysis using an sp 3 carbon atom as the probe.
- both the grid spacing and the size of the lattice space for which data points are calculated will depend on the size of the molecule and the resolution desired.
- the steric fields are set at a cutoff value (maximum value) as in standard CoMFA for lattice points whose total steric interaction with any side-chain atom(s) is greater than the cutoff value.
- One difference from the usual CoMFA procedure is that atoms which are separated from any template-matching atom by one or more rotatable bonds are set to make reduced contributions to the overall steric field.
- An attenuation factor (1 - "small number”) is applied to the steric field contributions which result from these atoms.
- the attenuation factor produces very small field contributions (ie: [0.85] N ) where N is the number of rotatable bonds between the specified atom and the alignment template atom.
- This attenuation factor is applied in recognition of the fact that the rotation of the atoms provides for a flexibility of the molecule which permits the parts of the molecule furthest away from the point of attachment to assume whatever orientation may be imposed by the unknown receptor. If such atoms were weighted equally, the contributions to the fields of the significant steric differences due to the more anchored atoms (whose disposition in the volume defined by the receptor site is most critical) would be overshadowed by the effects of these flexible atoms.
- the derivation of a hydrogen-bond field is slightly different from the standard CoMFA measurement.
- the intent of the hydrogen-bonding descriptor is to characterize similarities and differences in the abilities of side chains to form hydrogen-bonds with unknown receptors.
- the topomeric conformation is also an appropriate way to characterize the spatial position of a side chain's hydrogen-bonding groups.
- hydrogen-bonding is a spatially localized phenomenon whose strength is also difficult to quantitate. Therefore, it is appropriate to represent a hydrogen-bonding field as a bitset, much like a 2D fingerprint, or as an array of 0 or 1 values rather than as an array of real numbers like a CoMFA field.
- the hydrogen-bonding loci for a particular side chain are specified using the DISCO approach of "extension points" developed by Y. Martin 12 and coworkers, wherein, for example, a carbonyl oxygen generates two hydrogen-bond accepting loci at positions found by extending a line passing from the oxygen nuclei through each of the two "lone-pair" locations to where a complementary hydrogen-bond donating atom on the receptor would optimally be. It is not possible with a bitset representation to attenuate the effects of atoms by the number of intervening rotatable bonds. Instead, uncertainty about the location of a hydrogen-bonding group can be represented by setting additional bits for grid locations spatially adjacent to the single grid location that is initially set for each hydrogen-bonding locus.
- each hydrogen -bonding locus sets bits corresponding to a cube of grid points rather than a single grid point.
- Table 4 The validation results shown in Table 4 were obtained for a cube of 27 grid locations for each hydrogen bonding locus.
- the single bitset representing a topomeric hydrogen-bonding fingerprint has twice as many bits as there are lattice points, in order to discriminate hydrogen-bond accepting and hydrogen bond-donating loci.
- the difference between two topomeric hydrogen-bonding fingerprints is simply their Tanimoto coefficient which now represents a difference in actual field values.
- Software which implements the hydrogen-bonding field calculations is provided in Appendix "B".
- Table 1 contains the density ratios from the quantitative analysis of the twenty data sets.
- a metric is considered valid/useful for an individual data set if the Patterson plot ratio is greater than 1.1; that is, there is greater than a 10% difference in the density between the ULT and LRT.
- the use of 1.1 as a decisional criteria is confirmed by an examination of the scatter diagrams of X 2 values versus their corresponding ratios as shown in Figures 8A and 8B. (The value of X is actually plotted in Figure 8B in order to separate the data points.)
- Figure 8A shows the plot of X 2 s having a value of greater than 3.84 (95% confidence limits) versus their corresponding ratios
- Figure 8B shows the plot of X 2 s (plotted as ⁇ X 2 ) having a value less than 3.84 versus their corresponding ratios.
- a ratio value of greater than 1.1 clearly includes most of the statistically significant ratios, while a ratio value of less than 1.1 clearly includes most of the statistically insignificant ratios. While this is not a perfect dividing point and there is some overlap, there is also some distortion of the X 2 values due to limited population sizes as discussed below. Overall, the value of 1.1 provides a reasonable decision point.
- a metric should not be determined on the basis of one data set from the literature.
- a single literature data set usually presents only a limited range of structure/activity data and examines only a single biological activity. To obtain a proper sense of the overall validity/quality of a metric, its behavior over many data sets representing many different biological activities must be considered. It should be expected for randomly selected data sets that due to biological variability, an otherwise valid metric may appear invalid for some particular set. An examination of the data in Table 1 confirms this observation.
- the X 2 values support the significance (or lack of significance) of the ratio values. However, for data sets 9, 13, 14, and 15 the 95% confidence limit is not met. As with all statistical tests, X 2 is sensitive to the sample size of the population. For these data sets the N was simply too low. This sensitivity is well demonstrated by the difference in X 2 for sets 14 and 20. The ratio values of the two sets are virtually identical, but the X 2 s differ significantly since set 14 has few points and set 20 many points. Thus, X 2 may be used to confirm the significance of a ratio value, but, on the other hand, can not be used to discredit a ratio value when too few data points are present. It can be clearly seen that the topomeric CoMFA metric appears to define a useful dimensional space (measures chemistry space) better for some of the target sets than for others.
- a metric need not be perfect to be valid. Even using an imperfect metric significantly increases the probability that molecules can be properly characterized based on structural differences. As the quality of the metric increases, the probability increases. Thus, metrics which appear valid by the above analysis with respect to only a few test data sets are still useful. Metrics, like topomeric CoMFA, which are valid for 85% (17/20) of the data sets yield a higher probability that structurally diverse molecules can be identified.
- Topomeric CoMFA distances can, therefore, be usefully used as a diversity measure in selecting which molecules of a proposed combinatorial synthesis should be retained in the combinatorial screening library in order to have a high probability that most of the diversity available in that combinatorial synthesis is represented in the library.
- a combinatorial screening library only one example of a molecular pair having a pairwise distance from the other of less than approximately 80 - 100 kcal/mole (belonging to the same diversity cluster) would be included. However, every molecule of a pair having a pairwise distance greater than approximately 80 - 100 would be included.
- the "fineness" of the resolution (the radius of the neighborhood in metric space) can be changed by using a different activity difference.
- the Patterson plot permits by direct inspection the determination of a neighborhood distance appropriate to any chosen biological activity difference. It is suggested, however, that for a reasonable search of chemistry space for biologically significant molecules, a difference of 2 log units is appropriate. The exact value chosen be adjusted to the circumstances. Clearly, the opportunity for real world perturbing effects to dominate the measure is magnified by using less than 2 log units difference in biological activity. This is another example of the general signal to noise ratio problem often encountered in measurements of biological systems. For more accurate signal detection less perturbed by unusual effects, the data sets would ideally contain biological activity values spread over a wider range than what is usually encountered.
- the neighborhood radius predicted from an analysis of the topomeric CoMFA metric can now be used to cluster molecules for use in selecting those of similar structure and activity (such as is desired in designing a combinatorial screening library of optimal diversity).
- cluster analysis using topomeric CoMFA fields produced a classification of reagents that makes sense to an experienced medicinal chemist.
- topomerically aligned CoMFA fields of the 736 thiols are clustered, stopping when the smallest distance between clusters is about 91 kcal/mole (within the "neighborhood" distance of 80-100 found for these fields in the validation studies), 231 discrete clusters result differing from each other in steric size by at least a -CH 2 - group.
- the critical aspect of this clustering result is that the structurally most logical clustering was generated with a nearest neighbor separation of 91, in the middle of the 80 - 100 neighborhood distance determined from the validation procedure to be a good measure of similarity among the molecules in topomeric CoMFA metric space. That is, the neighborhood distance of approximately 80 - 100 (corresponding to an approximate 2 log biological difference) predicted from the topomeric CoMFA validation, generates, when used in a clustering analysis, logical systematic groupings of similar chemical structures.
- the exact size of the neighborhood radius useful for clustering analysis will vary depending upon: 1) the log range of activity which is to be included; and 2) the metric used since, in the real world, different metrics yield different distance values for the same differences in biological activity.
- the topomeric CoMFA metric can be used to distinguish diverse molecules from one another - the very quantitative definition of diversity lacking in the prior art which is necessary for the rationale construction of an optimally diverse combinatorial screening library.
- the discovered validation method of this invention is not limited to the topomeric CoMFA field metric but is generalizable to any metric.
- any metric once any metric is constructed, its validity can be tested by applying the metric to appropriate literature data sets and generating the corresponding Patterson plots. If the metric displays the neighborhood behavior and is valid/useful according to the analysis of the Patterson plots set forth above, the neighborhood radius is easily determined from the Patterson plots once an activity difference is selected. This neighborhood radius can then be used to stop a clustering analysis when the distance between clusters approaches the neighborhood radius. The resulting clusters are then representative of different aspects of molecular diversity with respect to the clustered property/metric.
- a metric by definition, is only used to describe something which has a difference on a measurement scale. This necessarily implies a "distance” in some coordinate system. Mathematical transformations of the distances yielded by any metric are still "distances" and can be used in the preparation of the Patterson plots. For instance, the topomeric CoMFA field distances could be transformed into principal component scores and would still represent the same measure. Since the validity of the metric is not dependent on the particular chemical/biological assays used to establish its validity, the metric can be applied to assemblies of chemical compounds of unknown activity. Clustering of these assemblies using the validated neighborhood radius for the metric will yield clusters of compounds representative of the different aspects of molecular diversity found in the assemblies. (It should be understood that active molecules for any given assay may or may not reside in more than one cluster, and the cluster(s) containing the active compound(s) in one assay may not include the active compound(s) in a different assay.)
- Tanimoto 13 fingerprint similarity measure This is one of the 2D measurements frequently used in the prior art to cluster molecules or to partially construct other molecular descriptors. (Technically descriptors containing a Tanimoto term are not metrics since the Tanimoto is not a metric). 2D fingerprint measures were originally constructed to rapidly screen molecular data bases for molecules having similar structural components. For the present purposes, a string of 988 has been found convenient and sufficiently long.
- a Tanimoto 2D fingerprint similarity measure (Tanimoto coefficient) between two molecules is defined as:
- Tanimoto fingerprint simply expresses the degree to which the substructures found in both compounds is a large fraction of the total substructures.
- Brown, Martin, and Bures 3 of Abbott Laboratories presented clustering data generated in an attempt to determine which, if any, of the common descriptors available in the prior art produced "better clustering". "Better clustering" was defined as a greater tendency for active molecules to be found in the same cluster.
- One of the measures used was the Tanimoto 2D fingerprint coefficient calculated from the structures of the entire molecules (not just the side chains). Proprietary and publicly unavailable data sets were used by the Abbott group which covered a large number of compounds for which the activity or lack of activity in four assays had been experimentally verified over many years of pharmacological research.
- Tanimoto coefficient reflects a neighborhood property over a range of different biological assays
- 11 ,400 compounds from Index Chemicus containing 18 activity measures with 10 or more structures were analyzed.
- Index Chemicus covers novel compounds reported in the literature of 32 journals.
- Lack of a reported activity was assumed to be an inactivity although, in reality, the absence of a report of activity probably means that the compound was just untested in that system.
- this assumption is a more difficult test in which to discriminate a trend than with the Abbott data base where it was experimentally known whether or not a molecule was active or inactive.
- all that is absolutely needed for this analysis is a high likelihood of having compounds that are "similar enough" in fingerprints to also be “similar enough” in biological activity.
- Table 2 shows the structures and activities analyzed. To convert this data to sigmoid plots, the data lists were examined for everything which was active, and a Tanimoto coefficient calculated (on the whole molecule) between every active molecule and everything else in the list. For plotting, the value of the number of molecules which were a given value (X) away from an active compound was determined. The proportion (frequency of such molecules) was plotted on the vertical axis and the Tanimoto coefficient on the horizontal axis. The bin widths for the X axis are 0.05 Tanimoto difference units wide, and the activity from Index Chemicus was simply "active" or "inactive".
- Figures 9A and 9B show the resulting plots for 16 of the 18 data sets broken down into sets of 8 (replication of these Figures in the priority applications did not pick up the ninth curve in each Figure, so that the ninth curve in each set has been ommitted from this application). Many of the curves have a sigmoid shape, but the inflection points clearly differ. Also, it is not clear what effect excluding the differences between active and inactive molecules has on the shape of the curves. To get an overall view, Figure 9C shows the cumulative plot for both series of 9 activities. This plot generally indicates that, given an active molecule, the probability of an additional molecule, which falls within a Tanimoto similarity of 0.85 of the active, also being active is, itself, approximately 0.85.
- Tanimoto similarity descriptor when a Tanimoto similarity descriptor is summed over an arbitrary assortment of molecules and biological activities, it is clear that molecules having a Tanimoto similarity of approximately 0.85 are likely to share the same activity. Thus, the Tanimoto similarity displays a neighborhood behavior (neighborhood distance of approximately 0.15) when applied to a large enough number of arbitrary sets of compounds. As will be discussed later, one of the more powerful aspects of the Patterson plot validation method is that it can provide a relative ranking of metrics and distinguish on what type of data sets each may be more useful. In this regard, it will be seen that the whole molecule Tanimoto coefficient as a diversity descriptor has unanticipated and previously unknown drawbacks.
- Tanimoto descriptor can be used in a unique manner in the construction of a combinatorial screening library.
- this descriptor can be used to provide an important end-point determination for the construction and merging of such libraries and, in addition, is a useful descriptor for constructing and searching the virtual library.
- the molecules must be first be divided into two categories, active molecules and inactive molecules, based on a cut off value chosen for the biological activity.
- One molecule of a pair must be active (as defined by the cut off value) before the pair is included in the sigmoid plot. Pairs in which neither molecule has any activity, as well as those pairs in which neither molecule has an activity greater than the cut off value, do not contribute information to the sigmoid plot.
- the sigmoid plot does not use all of the information about the chemical data set under study. In fact, it uses a limited subset of data derivable from the more general Patterson plot described above. As a consequence very large sets of data (or sets for which both the activity and inactivity in an assay are experimentally known) are needed to get statistically significant results from the sigmoid plots.
- the Patterson plot clearly displays a great deal more information inherent in the data set which is relevant to evaluating the metric.
- the validity and usefulness of the metric can be quickly established by examining the Patterson plots resulting from application of the metric to random data sets.
- a metric may reflect a neighborhood property (such as in a sigmoid plot), but at the same time may not be a particularly valid/useful metric or may have limited utility.
- all pairs of molecules and their associated activities or inactivities contribute to the validity analysis and to the determinations of the neighborhood radius.
- the cut off value for biological activity was chosen to be 60 ⁇ M.
- “active” molecules were those with an Al agonist potency of 60 ⁇ M or less, and “inactive” molecules were those with a potency greater than 60 ⁇ M.
- Tanimoto appears to be a good descriptor for only 50% of the data sets (10/20 data sets with a ratio greater than 1.1). At first glance this is surprising in light of the original Abbott data, but, on second consideration, it is consistent with the observed significant individual variability of the plots obtained from the Index Chemicus analysis in Figures 9A and 9B.
- the Patterson plots confirm that the Tanimoto coefficient does display a neighborhood property for some data sets, but clearly it is less valid/useful for other sets. And it is not as consistent as the topomeric CoMFA or the side chain Tanimoto descriptor which were valid 85% (17/20) and 80% (16/20) of the time respectively.
- the side chain Tanimoto metric also appears to be valid/useful. This is an extraordinarily surprising result since this metric has always been thought of in the prior art as useful only as a measure of whole molecule similarity. Overall, it compares favorably with topomeric CoMFA.
- the side chain Tanimoto metric does not appear valid with respect to sets 3, 8, 12, and 18. Clearly set 8 had too little data for either the topomeric CoMFA or the side chain Tanimoto descriptors.
- both the topomeric CoMFA metric and the Tanimoto metric define metric spaces where biological properties cluster (that is; the metrics are sensitive to biologically relevant molecular strucutral differences), a descriptor combining the two metrics was construcuted.
- a combined descriptor has been identified which is the best diversity descriptor discovered to date.
- This descriptor has been validated and has been found to be far superior to any previously considered metric in its ability to identify a neighborhood of similarity for design purposes.
- This descriptor, a weighted combination of the topomeric CoMFA descriptor and the Tanimoto descriptor defines a distance measure as:
- This descriptor has a ratio greater than 1.1 in all 20 out of the 20 test data sets, and, in fact, averages a ratio of 1.55.
- a neighborhood distance of 0.240 corresponding to a biological activity difference of 2 log units
- this level will be maintained as more and more data sets are added to the validation group.
- the results of performing validation studies on the combined descriptor and other possible metrics using the Patterson plot method of this invention and the 20 described data sets result in the following data:
- the design process may be thought of as a filtering process in which the molecules available in a combinatorially accessible chemical universe are run through consecutive filters which remove different subsets of the universe according to specified criteria.
- the goal is to filter out (reduce the numbers of) as many compounds as possible while still retaining those compounds which are necessary to completely sample the molecular diversity of the combinatorially accessible universe.
- the basic design method of this invention along with several ancillary considerations is shown schematically in Figure 11 using the filter analogy. For this example only two sets of reactants are considered with one reactant of each set being contributed to each final product molecule. The reactants are shown forming the top row and first column of a combinatorial matrix A.
- each filter 4 Beside each filter step is indicated the corresponding text section describing that filter. Also set out opposite each filtering step is an indication of the software and its source required to implement that step.
- reactants with unusual elements are normally excluded when considering the synthesis of organic molecules.
- tautomerization of structures can cause problems when searching a universe of reactants data base either by missing structures that are actually present or by finding a specific functional group which is really not there. The most common example of this is the keto-enol tautomerism.
- possible tautomeric reactants must be examined and improper forms eliminated from consideration.
- reactants may be provided in solvent, as salts with counter-ions, or in hydrated forms. Before their structures can be analyzed for diversity purposes, the salt counter-ions, solvent, and/or other species (such as water) should be removed from the molecular structure to be used.
- reactants may contain chemical groups which would interfere with or prevent the synthetic reaction in which it is desired to use them.
- either different reaction conditions must be used or these reactants removed from consideration.
- extraction of the products resulting from some reactants may be difficult using the proposed synthetic conditions.
- another synthetic scheme must be used or the reactants removed from consideration.
- Price and availability are not insignificant considerations in the real world. Some reactants may need to be specially synthesized for the combinatorial synthesis or are otherwise very expensive. In the prior art, expensive reactants would typically be eliminated before proceeding further with the library design unless they were felt to be particularly advantageous.
- One of the advantages of the method of this invention is that the decision whether to include expensive reactants may be postponed until the molecular structures have been analyzed by a validated descriptor. With confidence that the validated descriptor permits clustering of molecules representing similar diversity, often another, less expensive, reactant can be selected to represent the diversity cluster which also includes the expensive molecule.
- the specifics of any particular contemplated combinatorial synthesis may suggest additional appropriate filtering criteria at this level. In Figure 11 the effect on the number of possible products of removing only a few reactants is easily seen in matrix B. For each reactant removed, whole rows and columns of possible products are excluded.
- a library designed for screening potential pharmacological agents imposes it own limitations on the type and size of molecules. For instance, for drug discovery, toxic or metabolically hazardous reactants or those containing heavy metals (organometallics) would usually be excluded at this stage. In addition, the likely bioavailability of any synthetic compound would be a reasonable selection criteria. Thus, the size of the reactants needs to be considered since it is well known that molecules above a given range of molecular weights generally are not easily absorbed. Accordingly, the molecular weight for each reactant is calculated. Since the final molecular weight for a bioavailable drug typically ranges from 100 to 750 and since, by definition, at least two reactants are used in a combinatorial synthesis, reactants having a size over some set value are excluded.
- Another aspect of bioavailability is the diffusion rate of a compound across membranes such as the intestinal wall. Reactants not likely to cross membranes (as determined by a calculated LogP or other measure) would usually be eliminated. At the present time, although the CLOGP for reactants makes only a partial contribution to the product CLOGP, it is believed that if any reactant has a CLOGP greater than 10, it will not make a usable product. Accordingly, the CLOGP is calculated for each reactant and only those with CLOGP ⁇ 10 are kept. Again, in any particular case, a different value of CLOGP could be utilized.
- an ideal combinatorial screening library will: 1) have molecules representing the entire range of diversity present in the chemical universe accessible with a given set of combinatorial materials; and 2) will not have two examples of the same diversity when one will suffice.
- the goal is to obtain as complete a sampling of the diversity of chemical space as is possible with the fewest number of molecules, and, coincidentally, at lowest cost.
- the second opportunity occurs after all the combinatorial possibilities from the chosen reactants (and core) have been selected.
- the method of the present invention utilizes both opportunities by using validated metrics appropriate to each situation.
- any metric which has been shown by the Patterson plot validation methodology to be valid/useful when applied to reactants may be used at this stage of the library design process.
- the principle reason is that the accumulated observation of biological systems is that ligand-substrate binding is primarily governed by three dimensional considerations. Before a reactive side group can get to the active site, before appropriate electrostatic interactions can occur, before appropriate hydrogen bonds can be formed, and before hydrophobic effects can come into play, the ligand molecule must basically "fit" into the three dimensional site of the substrate.
- a principal consideration in designing screening libraries should be to sample as much of the three dimensional (steric) diversity of the combinatorial universe as is possible.
- the initial method of the present invention does this by utilizing the validated topomeric CoMFA metric to analyze the steric properties of the proposed reactants.
- a second reason for applying a steric metric to the reactants is that all of the three dimensional variability of the products resulting from a combinatorial synthesis resides in the substituents added by the reactants since the core three dimensional structure is common to all molecules in any particular combinatorial synthesis. In a sense it would be redundant to measure the contribution to each product molecule of a core which is common to all the products.
- a third reason for applying a three dimensional metric to the reactants is that a sterically sensitive metric distinguishes differences among molecules that are not revealed using other presently known metrics.
- the topomeric CoMFA metric is more sensitive to the volume and shape of the space occupied by a molecule than is, for instance, either the side chain or whole molecule Tanimoto descriptor.
- Figure 12 provides an illustrative example of this feature drawn from the thiol study which confirms what was seen in the Patterson plots of the topomeric CoMFA and Tanimoto whole molecule descriptor.
- Figure 12 shows three clusters labeled 24, 25, and 29 for which the Tanimoto whole molecule fingerprint metric does not indicate any substantial difference in molecular structure among the molecules, labeled (a) through (f), making up each of the clusters.
- the large panel A in the upper right of Figure 12 shows orthogonal 3D views of the volume differences within clusters 24, 25, and 29 comparing each of the molecules that are not in the majority steric field cluster.
- the Cluster 24 figure B at the top shows four contours (yellow, green [hidden], red, and blue) indicating the differences in volumes occupied by compounds 24(a), 24(b), 24(c) and 24(f) compared to compounds 24(d) and 24(e) which are found in the same steric field cluster, number 10.
- the middle C and bottom D figures in the large panel A show similar distinguishable volume differences for Clusters 25 and 29.
- a diversity selection based on three dimensional steric measures begins by: 1) generating 3D structures for the reactants; 2) aligning the 3D molecular structures according to the topomeric alignment rules; 3) generating CoMFA steric field values for the reactants including, if desired, hydrogen bonding fields, and applying a rotatable bond attenuation factor; and 4) calculating pairwise topomeric CoMFA differences for every pair of reactants.
- the steric diversity of the reactant space has been mapped into the topomeric CoMFA metric space.
- the method of the invention clusters (using hierarchical clustering) the reactants in topomeric CoMFA space so that reactants having a pairwise difference of less than approximately 80 -100 units are assigned to the same cluster. Put another way, clustering is continued until the inter-cluster separation is greater than approximately 80 - 100 units. (If desired, there is some leeway in choosing the exact neighborhood radius in and about the neighborhood range to use for any given biological system.
- the clustering process now identifies groups (clusters) of reactants having steric diversity from one another but also having the same steric properties within each cluster. Or put in terms familiar to medicinal chemists, the molecules of each cluster should be bioisosters. For purposes of designing a combinatorial screening library which has within it molecules representing the full range of steric diversity present in the universe of reactants, it is now only necessary to select one reactant from each cluster for inclusion in the library. A reasonable way to select the one reactant from each cluster would be to select the lowest priced or most readily available one. However, additional criteria may be considered. The diverse reactants remaining at matrix D need not be adjacent to each other on the combinatorial matrix and are only shown this way for graphic convenience. At this point the first stage of library design has been completed.
- topomeric CoMFA metric to measure the three dimensional structural diversity of the reactants
- any metric 1) reflective of the three dimensional properties of molecules; and 2) validated as taught above, could be applied to the reactants to be used in a combinatorial synthesis in the manner taught above.
- the teaching of this invention is not limited to the use of the topomeric CoMFA metric, but also includes the use on reactants of all validated three dimensional metrics.
- initial studies of topomeric hydrogen bonding fields indicate that it should be a very useful metric. For those reactants expected to form large number of hydrogen bonds, this may be the metric of choice.
- the hydrogen bonding metric would be used as an adjunct to the topomeric CoMFA metric in those situations. There may be situations where a sterically sensitive metric is not needed, in which case it should be clear that any valid metric appropriate to reactants could be used.
- the structures of the product molecules can be combinatorially determined based on the synthetic reaction scheme and any desired cores.
- the reactants are used to build the structures of the combinatorial products using LEGION and are stored in molecular spread sheets.
- matrix E the products which can still be built from the available reactants are shown as asterisks in each matrix location.
- the product molecules should be examined with many of the same selection criteria applied to reactants.
- molecular weights should be calculated and those compounds which have molecular weights over a predetermined value should be rejected.
- a value of 750 is used at this time as a representative weight above which bioavailability may become a problem.
- CLOGP should be calculated and any proposed molecule with a value under -2.5 or over 7.5 rejected. The number of structures eliminated at this point will depend in part both on the chemistry involved and the molecular weight range retained at the reactant stage. These additional product structures which are eliminated are reflected in matrix G. E. Removal of Non-Diverse Products
- one combination of core and reactants is similar (due to the similarities of structures contained in the core to the structure of the reactants) to another combination of core and reactants. That is, when the reactants are combined with the core molecule, it is possible that substructures within the core can combine with different substituents to form similar structures. Clearly, it would be redundant to screen both. How to select product molecules has been a vexing problem in the prior art, and this is one reason why the prior art has basically been concerned with clustering criteria. The general approach taken in the prior art to avoid oversampling combinatorial product molecules representing the same diversity has been to cluster the molecules and then maximize the distance between clusters with whatever metric was applied to the products.
- the library design method of this invention again makes use of the neighborhood principle to solve this problem.
- the method of this invention specifically does not use a metric to cluster product molecules.
- the neighborhood definition may be used to decide which product molecules to retain in the final screening library and, correspondingly, when the appropriate number of product molecules have been selected for inclusion in the library. Essentially, starting with one product molecule, additional molecules are selected as far apart as possible (in the validated metric space) from any molecule already in the library until the next molecule to be selected would fall within the neighborhood distance of a molecule already included.
- the Tanimoto 2D whole molecule similarity coefficient is used for the final product selection.
- this metric possesses the neighborhood property. Accordingly, from the combinatorial products either a first product is arbitrarily chosen for inclusion in the library or an initial seed of one or more products may be specified. (If an arbitrary product molecule is chosen, Tanimoto coefficients are calculated for all other molecules to the first molecule and a second molecule with the smallest Tanimoto coefficient [greatest distance - least similarity] from the first is chosen for inclusion.) For the efficient selection of additional molecules to be included, the distance (1 - Tan. Coeff.) between each additional molecule and all molecules already included in the library is calculated.
- the distance to the closest molecule already in the library is identified. These closest distances for each additional molecule are compared, and the additional molecule whose closest distance is the greatest is selected next for inclusion; that is, the molecule which is farthest away from the closest molecule in the library is selected. A new set of distances is calculated and the process continued, selecting one molecule at a time, until no more molecules remain which are farther away than 0.15 ([1 - 0.85] the definition of a Tanimoto "distance" using the neighborhood value of 0.85). While this example is presented in terms of the Tanimoto similarity coefficient, any validated whole molecule metric and its neighborhood definition may be used with this sampling procedure.
- the value of 0.85 for the Tanimoto neighborhood definition originally appeared in the sigmoid plots.
- the Patterson plots for the whole molecule Tanimoto in which the X 2 indicated significance were used to calculate the neighborhood value.
- the metric distances corresponding to 2-log and 3-log biological differences were determined by dividing the slope of the density determined line by the values 2 and 3 respectively. Over the data sets, the average metric distance for a 2 log biological difference was 0.14 and the average metric distance for a 3-log biological difference was 0.21. Since the Tanimoto distance of (1 - Tan.
- Figure 13 shows a plot of the Tanimoto 2D pairwise similarities for a typical combinatorial product universe in which there has been some selection of reactants based on diversity. As can be seen, a very large percentage of the products have similar structures (Tanimoto coefficients > 0.85).
- the sampling process outlined above results in the following. Molecules having pairwise similarities above approximately 0.85 have overlapping neighborhood radii as shown at 1 and one of each pair is excluded from the library. Molecules having pairwise similarities of approximately 0.85 have almost touching but not overlapping neighborhood radii as shown at 2 and are included in the library.
- Molecules having pairwise similarities significantly less than approximately 0.85 have no overlapping neighborhood radii as shown at 3 and are also included in the library. Excluding molecules with a Tanimoto similarity greater than 0.85 will eliminate a significant number of molecules in this representative product assembly. This reduction is also reflected in matrix H. While the circles of similarity shown in Figures 13 represent convenient conceptualizations of the neighborhood distance concept, it should be remembered that most metrics will not define a space in which the "distance" corresponds to an area or volume. In particular, a Tanimoto similarity space does not have this property, yet the "similarity" to a neighbor can be defined and is very useful.
- a specific example illustrates the dramatic power of the final selection stage in the design process.
- a proposed combinatorial screening library was designed using thiols and sulfonyl chlorides as reactants. (Many of the same thiols were considered in the study discussed earlier.) The original 716 thiols and 223 sulfonyl chlorides considered would make 159,668 potential products. Topomeric CoMFA analysis indicated that 170 thiols and 61 sulfonyl chloride reactants represented diverse molecules for the purposes of this design and should be used in further library design. 10,370 combinatorial products were now possible. Graph 1 of Figure 14 shows the Tanimoto similarity distribution of the 10,370 possible products.
- 1,656 have been identified which represent the structural diversity of the large ensemble.
- An approximate 100: 1 reduction has been achieved without sacrificing the diversity of the combinatorially accessible universe.
- these same 1,656 compounds can be tested in any number of biological assays with a high degree of assurance that even in assays with unknown biological activity requirements, these compounds will present the diversity of compounds accessible through this combinatorial universe to the biological assays.
- a list of product structures and the reactant sources for each is available in the computer and can be output either in electronically readable or visually discernable form.
- This data defines the combinatorial screening library.
- the list of reactants is supplied to synthetic organic chemists. Actual synthesized molecules are then available for testing in the biological assays, typically on multiple well plates.
- the list of products from each library design can be used to create a definition of a larger combinatorial screening library when merged with other such libraries as discussed below.
- the combinatorial screening library designed by the method of this invention is both locally diverse (no two reactants representing the same steric space are present) and globally diverse (no two products having overall similar structures are present). Such a library thus meets the desired combinatorial screening library criteria of being representative of the diversity of the entire combinatorially accessible chemistry universe while at the same time not containing more than one sample of each diversity present (no oversampling). An optimally diverse combinatorial screening library has thus been achieved. By designing an optimally diverse screening library, a reduction in the number of combinatorially generated structures which need to be synthesized and tested of substantially greater than 10 2 - 10 3 should be possible.
- each step provides an opportunity to identify and explore compounds having similar structural features.
- the library design itself identifies and permits a directed search for compounds from the utilized combinatorial universe most likely to have activity similar to the lead compound. The same procedure is followed if another valid metric, not the Tanimoto similarity) was used to create the library. Then all compounds within the neighborhood distance to a compound already in the library were excluded and the first place to look would be for compounds which fall within the neighborhood distance. The process is exactly identical to that followed using the Tanimoto descriptor.
- a validated metric would be used to map the lead and all other compounds in the assemblage to be examined into the metric space; ie, the metric characteristics/values are determined for all possible compounds.
- reactants possibly substituents
- a metric validated on reactants would be used.
- whole molecules a metric validated on whole molecules would be used. Metric differences between the lead molecule and all the other molecules would then be calculated. All molecules with metric distances to the lead within the neighborhood distance of the validated metric should have similar biological activities.
- the resolution obtainable with this procedure depends upon how well the structural diversity of the activity island is represented by the molecules in the original assemblage. That is, if only a portion of the activity island structural diversity is represented in the assemblage of molecules, that is the only part of the island which can be explored. Alternatively, perhaps only the island's rough outline can be perceived. Within the constraints of the diversity present in the assemblage, exploration of the full extent of the island and of the space within its boundaries can be accomplished with the guidance of the validated metric with which the island is mapped. To explore the island further it is only necessary to identify molecular structures not included within the original assemblage with which to test the unknown territory.
- the availability of validated metrics enables yet another method of rationally directed lead optimization from a knowledge of the structure of a lead molecule which was not identified from screening an optimally diverse combinatorial screening library.
- the reactant screening process is utilized backwards to identify similar molecular structures, and then the product screening process is utilized to confirm structural similarity of proposed products to the lead.
- Two cases are important. The first involves lead molecules which can be synthesized directly from reactants. In this method, the lead molecule would be analyzed to determine from what constituent reactants it may be synthesized. These reactants would then be characterized using a reactant metric such as topomeric CoMFA.
- Molecules in databases of potential reactants would be characterized using the reactant metric and searched for reactants falling within the neighborhood radius of each of the original reactants.
- the identified reactants will provide a basis for building proposed products having the same structural characteristics (diversity) as the original lead compound.
- its similarity in metric space to the lead would be checked using a product appropriate metric to make sure that it falls within the neighborhood radius of the lead.
- the second case involves lead compounds in which substituent groups are bonded to a central or core molecule.
- the reactants which form the basis of the substituents as well as the core molecule would then be characterized using appropriate validated metrics.
- molecules in databases of possible reactants and core molecules would be characterized with validated metrics and searched for molecules falling within the neighborhood radius of each of the original reactants and core.
- the molecules thus identified would provide a basis for building proposed products with structural diversity similar to the lead compound. Again, before synthesis, the proposed products would be evaluated with an appropriate metric to confirm that they fall within the neighborhood distance of the lead compound.
- one such useful preorganization involves dividing the candidates into series of molecules accessible by some common synthetic route, and thus describable in terms of a core and reactants.
- the synthetic route used to create the lead would be the first investigated and other sets of alternative routes explored secondarily.
- a combinatorial SYBYL Line Notation (cSLN) affords a useful description of such a series of molecules.
- Molecules represented by a cSLN would be considered for overall similarity to an active lead molecule in the manner discussed above. Using validated metrics, it is most efficient to: 1) first identify each of the individual lists of reactants within the cSLN with the most similar side chain within the active lead; 2) next, to consider the similarity of the "core” within the lead (the atoms remaining after the side chains are identified) to the non-variant core within the cSLN; and 3) then, if the "core" similarity is not so low that this series of molecules can immediately be excluded, to order the variation lists by similarity to the corresponding side chains within the lead.
- the final selection (sampling) methodology of this invention has broader uses than yet described. So far, this disclosure has been primarily concerned with the design of a combinatorial screening library based upon either sets of reactants or sets of reactants and central cores. Each combinatorial screening library based on these materials only explores the diversity of that part of the chemical universe accessible with those compounds. Unless as much of the diversity of the entire combinatorially accessible chemical universe is explored in a screening library as is possible, there is no assurance that a molecule possessing activity with respect to any particular unknown biological assay will be found. Clearly, the useful diversity of the combinatorially accessible chemical universe can only be explored with as many sets of reactants attached to as many cores as is possible.
- combinatorial screening libraries based on multiple reactants and multiple cores would be desirable. Just such libraries can now be created through the use of the virtual library discussed later. However, even with screening libraries constructed with the method of this invention discussed above, the simple addition to each other of many such libraries will quickly increase the total number of molecules which need to be screened. Worse yet, since many of the possible reactants used for combinatorial synthesis with different cores have similar structures, and since many of the possible cores used for combinatorial synthesis may differ little from each other, it is highly likely that much of the same diversity is represented to a greater or lesser extent in each of the libraries generated from these materials. Simply combining the libraries would again result in oversampling of the same diversity space. It would clearly be more useful and economical (efficient) in terms of time, money, and opportunity to use additional screening to explore different aspects of the diversity of the chemical universe.
- neighborhood selection (sampling) criteria also provides a method to combine combinatorial screening libraries to avoid this oversampling problem.
- each molecule of a second library is added to the first library if the molecule does not fall within the neighborhood radius of any molecule in the first library as supplemented by all the added molecules from the second library. This process is continued until all the molecules in the second library have been examined. In this manner, only molecules representative of a different aspect of diversity are added from the second library to the first. Each successive library is added in the same manner.
- the molecules in a final combined library formed from smaller libraries selected according to the method of this invention represent diverse molecular compounds and have the optima] diversity which is desired of a general combinatorial screening library.
- the groups of molecules to be merged may be merged according to the above procedure if first, a subset of each group of molecules is selected according to the product sampling method of the design process. This will insure that similar molecules within each group are eliminated.
- the resulting merged library will not be optimally diverse, but it should not redundantly sample the diversity present in the separate groups.
- the 2D Tanimoto fingerprint metric is useful in performing the library additions.
- the 2D Tanimoto similarity coefficient of each molecule in the first library to all molecules in a subsequent library are calculated.
- Each molecule of the second library is added to the first library if the molecule does not fall within a 0.85 Tanimoto coefficient (the neighborhood radius) of any molecule in the first library as supplemented by all the added molecules from the second library.
- this selection method guarantees a combined library in which all of the accessible diversity space is represented with little likelihood of oversampling.
- An example of three prior art libraries not designed with the method of this invention which might be merged using the neighborhood sampling criteria is shown in Figure 15.
- Figure 15 shows the distribution of molecules plotted according to their Tanimoto 2D pairwise similarity of the Chapman & Hall Dictionary of Natural Products, Dictionary of Pharmacological Agents, and Dictionary of Organic Compounds (CD ROM Versions). It is immediately clear from Figure 15 that simply adding the three libraries together would produce a combined library in which most of the compounds would be very similar to each other (Tanimoto similarities >0.85). Further redundant similarity would be expected from a comparison of the similarities between the molecules in the three libraries! The position of the 0.85 similarity point to the bulk of the molecules in each library indicates that, most of the molecules in these databases would be excluded from a combined library formed by merging the databases by the procedure outline above.
- the methods of this invention are also applicable to problems outside the specific area of drug research.
- the notion of choosing compounds based on diversity is a general concept with many applications and is applicable any time the problem is presented of having more compounds than can usefully be tested/used.
- the example was given earlier of determining what compounds had the same structural diversity as a previously identified (biologically active) compound.
- the activity may be any chemical activity.
- the universe of chemicals from which only some are to be selected does not have to result from a combinatorial synthesis, but may result from any synthesis or no synthesis at all.
- An example of the later would be the solution to the question of selecting molecules of similar diversity from among those in a large corporate or catalog data base.
- an appropriate metric (remembering that different metrics are applicable in different circumstances) would be applied to all the compounds and clustering would result in compounds of the same diversity.
- the methods of this invention including metric validation, topomeric CoMFA metric characterization, end-point neighborhood sampling, lead compound optimization, and library design can all be applied separately and together to solve the selection problem.
- the two step sequential design process for selecting optimally diverse product molecule libraries set out so far in this application is necessarily computationally time consuming, limited to consideration of one set of synthetic reactions at a time, and eliminates at the first stage reactants which might be capable of generating products which would pass the product stage neighborhood filtering criteria.
- the process is computationally time consuming since, for any given set of reactants, the steric metric must first be computed, the resulting descriptors clustered, and a selection of reactants made based on the neighborhood rule. Only after this first stage can the possible product molecules be determined, a second product metric calculated, and selection made of the final library members.
- the process is limited to one set of synthetic reactions at a time in the following sense.
- a particular organic chemical reaction scheme is identified as well as the core and possible reactants which may be used in the scheme.
- Each sequential step of library design is sequentially implemented and results in an optimally diverse library for that reaction.
- the entire process including all calculations must be repeated.
- Each combination of core and reactants generates a different library.
- the resulting libraries, individually derived, are then combined. This process also adds additional time to the assemblage of a larger optimally diverse library.
- the product stage of the design is constrained by the reactant stage; that is, since it is desirable to generate as many diverse products as possible, some products may be sufficiently diverse (as confirmed by the product neighborhood metric) when created from similar reactants (those failing within a topomeric neighborhood cluster) by virtue of the mere combination of the reactants into the products, and such products should be included in the library.
- the virtual library can be used not only to select screening libraries, to find molecules with similar structures to a lead compound, to perform lead explosions, but, through the use of validated metrics, it can also be used to search for and select compounds likely to have similar biological or other physical properties from across the broader chemical universe. In fact, as will be seen below, use of the virtual library opens up possibilities for searching the accessible chemical universe in ways not heretofore possible.
- use of the virtual library is not limited to finding molecules derivable from known synthetic combinatorial reactions, but is generally applicable to molecular selection.
- the ability to create and search the virtual library relies upon the power of the neighborhood property of validated metrics to distinguish the similarity or dissimilarity of molecular properties between molecules.
- the creation of a virtual library using validated molecular descriptors enables methods to identify compounds of interest from many possible compounds and is particularly applicable to identifying compounds of interest from extraordinarily large numbers of compounds.
- the application of these novel methods speeds the searching operation and in some ways extends the types of searching criteria which may be used.
- construction of a virtual library makes it possible to identify compounds of interest by an exhaustive search through all possible compounds from a series of known synthetic reactions - thus providing a capability which does not currently exist otherwise.
- the virtual library provides a large number and variety of ways to select a subset of compounds from a very large number of compounds. The number of compounds from which to make the selection is likely to range in the trillions of compounds, based only on known synthetic reactions and commercially available reagents appropriate for each reaction.
- the virtual library is not limited to such combinatorial compound universes and these universes are disclosed by way of an example of the methodology of the discovery, not a limitation thereof.
- the significant aspect of being able to create a virtual library using validated metrics is the ability to identify from the large universe of compounds those with related properties and/or structural characteristics without having to examine individual structures; in other words, to do structural searches without directly comparing (looking at) structures. This is made possible by precalculating, as much as possible, characteristics for the component parts of the product structures.
- the beginning point for this method is the construction of a database, or "virtual library", of possible chemical compounds, products, which can be synthesized from a common reaction.
- the database of compounds, "virtual library”, to which the method of this invention may be applied is an assembly of the combinatorially derived product structures resulting from any number of synthetic reactions.
- tens of reactions are used to construct the database (virtual library) of interest.
- the total number of possible product compounds becomes astronomically large very quickly. For instance, there are approximately 500 commercially available molecules having reactive diamino groups and approximately 15,000 commercially available reactants which will react independently with each of the amino groups. Combinatorially there can therefore be generated 15,000 X 15,000 X 500 (112 billion) possible product molecules from this one reaction scheme alone.
- a fundamental part of the discovery of how to create and use a virtual library is a method to precompute properties based on 1 + N 1 + N 2 + N 3 + ... N M structural variations which can be used to exactly, or with useful degree of approximation, predict the 1 ⁇ N 1 ⁇ N 2 ⁇ N 3 ⁇ ... N M product structure properties which arise from all combinations of the structural variations about the 1 core at all M substitution sites.
- the variable parts of a combinatorially derived molecule were referred to either by reference to their source (reactants) or their molecular configuration when attached to the core (side chains).
- structural variations is appropriate for the groups appended to a core. The reasons for adopting this term will become clear later during the discussion of searching the virtual library with respect to non-combinatorially derived structures.
- Figure 16 shows in schematic form a representation of three structural variations attached to a central core.
- each possible product structure arises from combining the core substructure with exactly one of the N, choices in the set of structural variations ⁇ R, ⁇ , exactly one of the N 2 structural variations in the set ⁇ R 2 ⁇ , etc.
- the values associated with the product compound are exactly the sum of the appropriately created structural variations.
- the overall process of virtual library construction is summarized in the flowchart of Figure 17.
- the first step in the creation of the virtual library is to create for each possible structural variation (variable part) a file containing various parameters/characteristics associated with that structural variation.
- the file may contain information on the price, source, availability, MW, and logP.
- the metric characteristics for the structural variation resulting from the application of validated metrics to the structural variation structure are included in the file. Other characteristics which might be used for searching may be added to the file. Similar files are created for core structures.
- any validated metric may be chosen to characterize the structural variations or cores.
- the same metrics, topomeric CoMFA and Tanimoto fingerprints, will be used as in the examples earlier.
- the second step in creation of the virtual library is a description of the chemical transformation represented by the chosen chemistry.
- the virtual library is then created by combinatorially combining all structural variations in the chemical transformation to generate virtual library descriptions of all possible product molecules.
- reagents refers to chemical starting materials which undergo reaction to produce the products.
- a reagent corresponds to a molecule used in a structural variation in the method, after some rearrangement of bonds.
- a key concept in constructing the virtual library is to organize the process of library definition so that it depends on a relatively small number of parameters which can be stored in a table so that each row in the table defines all the information that is necessary to specify a combinatorial library. While the following discussion addresses formation of the virtual library in terms of chemical transformations, cores, and reagents and/or structural variations which may be used, it should be appreciated that data in the virtual library may be generated by any cores and structural variations as long as the resulting compounds can be described by a cSLN. Thus, even product molecules which can not be synthesized by a known combinatorial reaction can be included in the virtual library and their structures searched.
- the first phase of construction of a combinatorial library to be included in the virtual library takes as input a description of the chemical transformation represented by that combinatorial library and a list of available reagents and produces as output all the part structures (a/k/a structural variations) found in the list of available reagents which are appropriate for the chemical transformation, along with all structure-invariant physicochemical properties of those fragments that might be useful in different types of subclass (subset) searches.
- the same general and biologically based elimination criteria can be applied to the proposed structural variations before selection of the structural variations for inclusion in the virtual library.
- structural variations which would be eliminated by the general or biologically based criteria can be flagged but still included. Having the structural variations flagged, few potential product structures are eliminated from the virtual library, but the products containing particular types of undesirable structural variations can still be removed during selection.
- RDATA an Oracle Table
- RDATA invariant physicochemical data computed about structural variations, typically the varying portions in a CSLN, with one record for each structural variation encountered in any cSLN constructed.
- data need not be recomputed when such structural variations are reencountered, a substantial savings in processing time.
- records will be added describing the properties of a -CH2CH(OH)R chain (structural variation) for each (new) epoxide-R reagent retrieved by the example record just given for the REAGENTS spreadsheet.
- Entering a new reaction into the system involves inputting the data for a new row to REACTIONS and at least two new rows to REAGENTS. This data entry operation is the only required data entry in preparation for virtual library production.
- the virtual library database of compounds for any one synthetic reaction is represented as a set of chemically bonded (connected) structural variations where the connecting elements may consist of a common core (one or more atoms which are identified in all members of the set). More than two variable sites may be involved.
- the list of structural alternatives therefore contains two or more elements, each of which represents a specific molecular fragment and a number of associated molecular properties. Table 6 and Table 7 below are produced by getacd.core.
- For each combinatorial scheme a set of files is generated. For a di-substitution scheme the first file defines the combinatorial scheme, and the second and third files describe the structural variations which can be utilized at the two sites.
- Table 7 shows the format in which the structural variations for the first variable site are listed, including both the structure in Sybyl Line Notation (SLN) and a set of related properties such as SUPPLIER, PRICE, molecular weight MW, estimate of hydrophobicity LOGP, and a field, CTOPS, which in encoded form represents the novel shape descriptor, the topomeric field (the steric field of the topomeric conformation) for the corresponding structural variation.
- SUPPLIER Sybyl Line Notation
- PRICE molecular weight MW
- estimate of hydrophobicity LOGP estimate of hydrophobicity LOGP
- CTOPS a field
- each selection in ⁇ R 2 ⁇ includes an OCH2 group connected to the core and each selection in ⁇ R 3 ⁇ contains a CH connected to the core
- the fingerprints corresponding to a selection from ⁇ R, ⁇ will describe the substructure formed by this selection connected to the core and also including an OCH2 connected to the core at site 2 and a CH connected to the core at site 3.
- this method can yield an exact result of the product fingerprint whenever the shortest connected path through the extended core is 5 atoms or more by OR-ing (a Boolean algebra manipulation) the fingerprints of each of the 3 structural variations in the example above.
- OR-ing a Boolean algebra manipulation
- There is no hazard of duplication since a fingerprint with a few exceptions notes only the presence of a connected fragment, not the number of occurrences. That is; either a bit is set in the fingerprint for that structure or it is not set. Duplicate occurrences of the same structure can not set the bit twice. In the few cases, such as ring and halogen structural features, where a count is maintained, correction for these bits of the fingerprint may be accomplished by explicit correction by count of structural variations plus core.
- the extended core is not large enough to assure exact construction of the product fingerprint from that of the pieces (i.e. some relevant fragments start in one structural variation, span the extended core and reach into the individual alternatives at another site).
- every compound is in fact possible for a set of one million products.
- explicit fingerprint computation is not feasible in any realistic time frame.
- an approximation is both acceptable and necessary.
- the purpose of the creation of the virtual library is to provide a basis for searching for molecules matching some subset criteria, the approximation method must ensure that such searches are reliable.
- a random sample of a statistically significant fraction (typically for a very large virtual library, 0.001) of the products is taken.
- Each sample product is checked to see how many bits are in the product but not in the fingerprint composed from the pieces.
- the largest observed difference value, MBITS is maintained for future calculations and is used to identify, for example, all products which might be similar to a given structure in the extreme case in which all MBITS missing bits were in fact those which would make every product most similar.
- the Tanimoto is defined as (#bits in common) / (#bits in either) for the similarity of two compounds' fingerprints.
- Tanimoto between two compounds.
- the actual product fingerprint cannot yield a higher Tanimoto than this, and almost always yields some value between the apparent Tanimoto and the upper bound. In some cases this estimates the largest possible Tanimoto to be greater than the actual maximum of 1.0; it serves no purpose to correct for this!
- fpcard and fp which together represent the two-dimensional fingerprint of the structural alternative and everything to which it is connected in all of the resulting products; this additional structure being needed to more fully represent the fingerprint of a product compound by that of the structural variations which combine to form it.
- Appendix G contains the code dbslnprepro which calculates and adds fpcard and fp.
- the fingerprint metric is calculated for each set of structural variations attached to a specific core, separate structural variations files containing the fingerprint data were required for each combination of core with the structural variations.
- the virtual library therefore contained a great deal of redundant data (structural variation files repetitively containing the same non-fingerprint data). Accordingly, a more efficient virtual library is constructed by locating the fingerprint files associated with each structural variation file and different cores in separate files. Thus, only one copy of each structural variation file (like Table 7) is required, and there is an associated fingerprint file containing fpcard and fp for every core with which the structural variation file is used.
- the virtual library keeps track of all the individual files in a master file.
- each line of the master file relates one Table 6 like file (CSLN) file with the appropriate structural variation files and fingerprint files.
- CSLN Table 6 like file
- the same structural variation files may now be used with more than one cSLN as long as the same type of chemical reaction is involved.
- Appendix G contains the code dbcslnprepro (a/k/a "power") which calculates fpcard and fp, writes the fingerprint files, and updates the master file.
- routines which the user applies to select subsets of the virtual library do not depend on this. Neither does the representation itself inherently depend on the assumption of known synthesis pathway. Therefore it can be applied to any situation in which the set of compounds of interest can be expressed concisely as a core and points of enumerated structural variations. This makes the scope of the method, in principle, cover virtually all of small molecule chemistry. In the limit, any molecule is divisible into such a representation where there may be only one "structural variation" known in each list. In fact, the practical advantages of the invention will only obtain when the number of structural variations is large.
- the techniques of constructing and searching the virtual library present the molecular researcher with powerful methods of discovery not previously possible and represent another major advance in the state of the art. Since the virtual library is constructed for purposes of finding molecular similarities in structure and function, a unique feature of the virtual library is that you can ask questions of similarity in two fundamental ways - providing, essentially, two sides of the same coin. The first way is in the design of screening libraries - subsets of the virtual library where what is sought are all those product molecules meeting some set of similarity criteria and not their structurally and/or functionally equivalent neighbors (as illustrated in Figure 1B).
- the second way is in expanding on a lead compound (lead explosion) - subsets of the virtual library where what is sought are all those product molecules meeting some set of similarity criteria to the lead and all the structurally and/or functionally equivalent neighbors.
- the search for the desired subsets may, at any given level of detail, take on aspects of one or the other of these two methods of inquiry. For instance, a search for all product molecules matching a lead compound may result in 10 million possibilities. In order to make the synthesis and actual screening more efficient, out of these 10 million, a screening library may be selected which does not sample the same neighborhood space more than once. This ability to perform different types of similarity searches underlies the discussion which follows.
- any of the characteristics associated in the virtual library file with each structural variation may be searched separately or in conjunction with other characteristics. Since validated metrics are used as descriptors for each structural variation, it is possible using only the data contained in the structural variation files to quickly identify those product molecules which could be formed from the structural variations similar in structure and biological activity to known molecules (such as lead compounds) or arbitrarily chosen molecules (screening libraries). With the virtual library, a structural search can be carried out without having to actually generate and compare any explicit structures of any possible product molecules. Subset libraries (screening libraries) representing molecules with selected characteristics can thereby be directly created by a search of the virtual library, and product structures created and generated only for those molecules included in the subset library. It is important to understand that the virtual library can be formed from any number of combinatorial synthetic schemes or can include molecules which, while not based on a combinatorial synthetic scheme, may be expressed in the form of a cSLN.
- the virtual library associates precomputed metric values with each structural variation.
- the virtual library has to date 170 billion possible product compounds representing 70,000 combinatorial reaction schemes over various cores, and it is being expanded monthly.
- the sheer size of the virtual library suggests that search times must be similarly enormous.
- real world searching rates of greater than 200 - 500 million compounds per hour have been routinely achieved with a single processor. Higher rates are achievable on a parallel processing computer with multiple processors such as are now available from several vendors including Silicon Graphics, Inc.
- the searching method of this invention independently searches each set of associated files generated by the virtual library construction method of the invention; in the case of the diamino example, a set of three files as outlined earlier. The reason each must be searched independently is that the searching program utilizes a knowledge of the number of sites (at which structural variations occurred in the synthetic scheme) to analyze the closeness of structure to the test molecule.
- any molecule falling within a neighborhood Tanimoto similarity of 0.85 of another molecule should possess similar structural and biological characteristics.
- a Tanimoto similarity of 0.85 provides the basic selection criteria for examining the virtual library data base.
- the fingerprint of the known molecule would first be compared to the fingerprint contained in every structural variation occurring at each of the two sites (2 ⁇ 15,000). The method determines how many of the bits set by the known molecule would be set by each structural variation. For all 15,000 choices at varying site R 1 (all 15,000 structural variations at R 1 ) the method compares the known molecule's fingerprints to the structural variation fingerprint.
- the resulting sum is compared to the Tanimoto neighborhood criteria.
- 100 bits were set by the known molecule. If the sum of bits totaled 65 and the neighborhood Tanimoto criteria of 0.85 (85 out of 100) were used, it would not be possible for any combination of those structural variations to form a molecule which would closely match the structure of the known molecule.
- the method also provides a check (MBITS) on the approximation routine used to calculate the fingerprints of the product molecules which would be formed from the two structural variations at sites R 1 and R 2 .
- MBITS a check
- Adding the 4 MBITS to the 65 only yields 69 which is clearly not within the required degree of Tanimoto neighborhood.
- the addition of the MBITS 4 would yield a total of 86, and the molecule formed from those structural variations would be considered close enough to check further.
- the fingerprints from the two structural variations involved are OR-ed (Boolean) so that commonly set bits are counted only once and then compared to the fingerprint of the known molecule. Only if the resulting number when added to the MBITS term is greater than 85, is the product molecule represented by the two variations considered a match and included in a subset library resulting from the search. While these additional calculations take extra time, it is only necessary to perform them on structural variation combinations which pass the first level of screening (set bits > 85). Therefore, typically only thousands of extra additions need to be calculated instead of millions, and the method is very fast. By the method of this invention hundreds of millions of possible compounds may be searched within a couple hours of computer time.
- This testing procedure is continued through every set of structural variation virtual library files. Different sets of files resulting from other two site synthetic schemes would be checked in a similar fashion.
- the known molecule was tested against a file set constructed from a synthetic scheme having three sites at which a structural variation could occur, the sum of the matching fingerprints contributed from three structural variations would be used and tested against the fingerprint of the known molecule in an identical manner.
- the actual method embodied in the software performs many quick checks on each set of structural variation files and quickly ascertains whether that set of files could yield a product structure with the required structural characteristics (fingerprint in this example). If the quick check indicates that the set of files could not yield the known molecule, the search is quickly advanced to the next set of files. In fact, on a parallel processing machine, many simultaneous searches are performed. Thus, the time to search the entire virtual library is relative short.
- the information derived from a search such as in the example, would identify those molecules which could be derived from a combinatorial scheme which most likely have the same structural and biological characteristics as the known molecule.
- all that is required is that the compounds can be described by a CSLN.
- the searching method of this invention could equally well find one or more of these molecules not derived from a combinatorial synthetic scheme as being likely to have the same structural and biological characteristics of the known molecule. The only difference in this later case is that no information about a possible synthetic route is available from the results of the search.
- Design Screening Libraries (Subsets of the Virtual Library)
- one single method is used to select among all possible products from one or more reactions which share a common core substructure.
- a bitset is used to represent all the possible products (generally in the tens of millions).
- One may seed the design with a set of preselected products.
- the selection may be random, or may be directed to maximize use of a reagent once selected (this matches the practical requirements for a laboratory two-step synthesis in which maximum use of the first step's intermediate structures offers a substantial advantage in speed and cost).
- any rule can be invoked to prioritize which compound to select next, since any remaining compound is allowable at every step. Examples of this type of search are given below.
- a selection of a screening library based on the same criteria as were discussed in the first part of this application is easily implemented using the virtual library.
- the library members are identified based on topomers (is the distance too small in topomer space) and on Tanimoto similarity separately, as was done in the earlier disclosed method.
- every reagent is always allowed, unlike the earlier method in which only a small subset of reagents made it through the reagent filter to the product stage.
- the earlier methods selected products based on maximal dissimilarity of product Tanimoto at each selection.
- the virtual library method Since by using the virtual library only the final selection set (all possible combinatorially created molecules meeting the selection criteria) is used, and does not depend upon or rely upon the ordering within a selected set (of reagents), the virtual library method is more flexible and in practice faster than the earlier disclosed method. In fact, since the product selection is not constrained by reagent stage selection, somewhat larger screening libraries result from using the virtual library. The overall process of using both the topomeric
- a subset of the virtual library may be based as well upon the combined topomeric-fingerprint metric described earlier.
- Code to implement this search, db both, is contained in Appendix L. A more extensive description of the code may be found in section G which follows.
- Subsets of molecules from the virtual library database may be selected based on descriptors typically including, but not limited to, the following:
- Subsets may be selected by applying by the following methods, including, but not limited to, simple filters, by requiring that filters meet a specific degree of similarity to reference compounds, or by applying proprietary design tools.
- the initial modes of subset selection may include:
- STIGMATA a procedure popularized by the scientists at Parke Davis queries, in which compounds are selected based on the presence of specific bits in a fingerprint (2D, atom pair, pharmacophore triplets, etc.). Commonly such a query is derived by reference to a set of desirable compounds, from which the bits present in all compounds in the set are derived.
- the topomeric 3D shape data within the Virtual Libraries actually describe fragments (structural variations) of molecules.
- the query molecule must be fragmented and the shapes of its fragments compared with the shapes of corresponding fragments (structural variations) in the virtual library.
- the difficulty is that a query molecule can be fragmented in so very many ways for searching against the virtual library containing in excess of 10 ⁇ 12 molecules.
- fragmentation table where each row constitutes a rule of the following sort: "for each occurrence of this particular structural feature combination (structural variation) in the query molecule, decompose the query molecule in a particular way specified in terms of this structural feature, and search only those combinatorial libraries that utilize specified reactions (sequences) and/or building blocks, mapping specified query fragments onto specified classes of building blocks".
- Each such query decomposition found generates a search of the virtual library, returning all those products whose sum of squares of differences in shape between corresponding product and query fragments is less than a user specified neighborhood distance threshold. Passing the query molecule (by means of a suitable computer program) against all the rows of this table generates all searches.
- Another row in the fragmentation table might designate a query decomposition into three fragments, with a structural feature R-[!r]NXN-[!r]R.
- the "core” or diamine component is searched first for fragments similar in shape to -NHCH(CH3)CH2NH- (see below for a description of the special features of core shape similarity). Core shape similarity is much rarer than side-chain shape similarity and so an efficient search process considers core similarity before considering side chain similarity.
- CLASS_ID equivalent in meaning and value to CLASS_ID in the REACTIONS table. Identifies a particular reaction sequence as it would be carried out in the laboratory. Only those virtual library records whose CLASS_ID matches this value will actually be searched.
- PRIORITY Allows a searcher to control the depth of a search. Lower values correspond to reactions which are less general, but whose products are more likely to resemble a matching query. Deeper searches will also consider rows having higher values of PRIORITY.
- SLN the structural pattern that will be matched within the query molecule. Each match found within the query molecule generates a decomposition of the query into fragments for topomeric similarity searching, as detailed elsewhere.
- REACTANTS Allows the developer of this table to limit application of a particular row to reactions involving particular classes of reactants.
- ATOMS Specifies, by reference to the fragment description with the SLN column, the bonds in the query whose breaking will generate the fragments to be used in topomeric field similarity searching.
- Tagamet and Zantac H2 antagonists
- the differences in steric (and any other fields) also contribute to the bioisosteric differences between two cores. Because there are potentially two or more possible attachment bonds in a core, there are two or more ways in which two or more cores may be compared. So the difference in fields is taken as the least of these possible differences.
- the successful generation of a topomeric descriptor for cores involves two advances.
- the relative position of attachment points has been introduced, for example, to distinguish ortho phenylene from para phenylene.
- the use of differences in x,y,z coordinates, rather than relative geometries such as distances and solid angles, provides a stronger differentiation needed between, for example, cyclic and acyclic cores.
- Appendix B This code calculates the hydrogen bond variation to be applied to the CoMFA steric field.
- Appendix E getacd,core This code handles the first phase of the construction of the virtual library.
- Appendix F SYB_MGEN_GPLS_COMFA_HEX *** CTOPS This code calculates the topomeric CoMFA field of each structural variation and adds it to the structural variation files. It also allows the computation and use of other than just steric fields.
- This Sybyl expression generator written in C, in invoked from SPL by a call %comfa_hex(Row Column). It returns an ASCII hexadecimal representation (0-9,a-f) for each CoMFA grid point in row "Row” and CoMFA column “Column” in the string which is seen as CTOPS in the input files.
- the encoding is as shown in the subroutine lookup_my_comfa_code(). As indicated, a missing value is assigned "0" and all legitimate values are assigned a number according to their numerical value. The binning is not quite linear; since the CoMFA values are infrequently between 10 and 30 this was empirically found to reproduce the exact CoMFA distances very well. The distances arising from this CTOPS description were validated against data sets to confirm that the encoding and decoding introduced no significant roundoff problems. The distance corresponding to the coded topomer field values of CTOPS are seen in the dbcsln_des routine called WhatsTheDifference().
- This program takes the description of the common core and solicits for each substituted position the SLN for the extended core. From this, and the list of structural variations, it computes the fingerprint and the fingerprint's cardinality for each structural variation and appends this as the fpcard and fp fields.
- the program creates a specified fraction of product compounds and computes their fingerprints exactly.
- the actual product fingerprint is compared to the fingerprint estimated from the pieces, and any discrepancy is noted by counting how many tested products have 0 missing bits, how many have 1, etc. The largest observed value is used as the MBITS parameter for the reaction.
- the new version of this code performs the same functions as the original code except that it writes separate files for fpcard and fp. In addition, it forms a master file to keep track of the association of all the files.
- This program takes one or more SLN structures as queries, along with the MBITS and the desired Tanimoto similarity, and the output of the dbcslnprepro run. It produces a listing of all products which may be above the Tanimoto cutoff value, by listing the index of each structural variation and both the apparent Tanimoto and the maximum possible Tanimoto (it is the maximum possible Tanimoto which defines the results).
- This code now reads master files and can read bitsets output from other files. Appendix I: dbcslnQS
- This program takes the results of the dbcslnprepro program, along with the MBITS and the Tanimoto similarity neighborhood, to select a designed subset based on Tanimoto similarity alone. Additional options allow one to remove from consideration products with a parameter outside of the desired range (such as molecular weight or logP or price), and to remove all products whose enumerated fields for one or more reagents are not in a list of acceptable choices (such as supplier).
- a parameter outside of the desired range such as molecular weight or logP or price
- the design selection consists of first removing products from consideration based on range of variables or acceptability of reagent. An initial selection is made, normally by random selection among all remaining products. Every product whose maximum possible Tanimoto similarity is above the cutoff is removed from further consideration. A product is then selected from among all remaining products, either randomly or by rule to continue using one of the reagents (R1, R2,etc) so long as possible (so long as any product remains using that reagent). This selected product's neighbors are removed from further consideration also, and this simple loop continues until no products remain or a maximum specified number of selections have been made. The loop is simply: select, remove neighbors in Tanimoto space.
- This program takes the results of the dbcslnprepro program, along with a value to define the topomeric similarity neighborhood, to select a designed subset based on topomeric similarity alone.
- This program operates exactly like dbcslnQS, except that the step at which neighbors are removed is based on topomeric similarity based on the CTOPS fields of the reagents, rather than the estimate of Tanimoto similarity. Thus after a selection it scans all remaining products to find every one which has a distance within the similarity radius, and marks these neighbors as unavailable for further consideration.
- Appendix K dbcsln_des
- This program takes the results of the dbcslnprepro program, along with the MBITS and the Tanimoto similarity neighborhood, plus a value to define the topomeric similarity neighborhood to select a designed subset based on Tanimoto similarity and topomeric similarity acting independently. This corresponds closely to the method of designed subset selection in the earlier described method.
- This code now reads and writes master files and bitsets.
- This program operates exactly like dbcslnQS, except that in addition to removing every
- Tanimoto neighbor of the selected compound we also remove the topomeric neighbors.
- it scans all remaining products to find every one which has a distance within the Tanimoto range, removes them, scans all remaining products to find every one which has a distance within the topomer range, and removes them.
- This program takes the results of the dbcslnprepro program, along with the MBITS and a way to scale topomeric distance, plus a similarity cutoff for the combined descriptor of topomer and Tanimoto, to select a designed subset based on Tanimoto similarity and topomeric similarity acting as one combined descriptor.
- This program operates exactly like dbcslnQS, except that the removal of neighbors is not based on either Tanimoto or topomeric distance by itself.
- This program takes the index results of dbcslnQS, dbclsn qstop, dbcsln both, dbcsln_des, or dbcslnsim and generates a full product structure SLN hitlist for them.
- This hitlist of products is suitable for treatment just as any set of chemical compounds - it loses its combinatorial identity as it becomes an assembly of independent chemicals.
- the new version of this code can now work with bitsets.
- This code is a set of subroutines used in many places, and, in particular, by the design programs.
- This code is a set of subroutines used in many places, and, in particular, by the design programs.
- This code contains subroutines for filtering undesired characteristics from product molecules.
- This code provides the additional routines need and called by the other code to handle bitsets.
- This code performs a topomeric CoMFA search for molecules similar to a query compound.
- This code performs the fragmentation required to implement a topomeric search of a query molecule not necessarily derived from a combinatorial synthesis.
- numbers indicate positions when substitution is on a ring, but chain length when substitution is on a chain (numbers separated by a colon indicate a range of chain lengths). Also, within a chain, letters indicate a position of
- a dot notation separates the three possible substituents on an alkenyl root, the substituent order being same carbon as the -SH substituent, then the position trans to the -SH, and finally cis to -SH.
- SMILES SMILES with the following concepts, among others. Hydrogens are explicit. Ring openings and closures begin with a number enclosed by [] and end with the matching number preceded by @ .
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Computing Systems (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Library & Information Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002245935A CA2245935C (en) | 1996-01-26 | 1997-01-27 | Method of creating and searching a molecular virtual library using validated molecular structure descriptors |
AU18479/97A AU1847997A (en) | 1996-01-26 | 1997-01-27 | Method of creating and searching a molecular virtual library using validated molecular structure descriptors |
EP97904095A EP0892963A1 (en) | 1996-01-26 | 1997-01-27 | Method of creating and searching a molecular virtual library using validated molecular structure descriptors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/592,132 US6185506B1 (en) | 1996-01-26 | 1996-01-26 | Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors |
US08/592,132 | 1996-01-26 | ||
US65714796A | 1996-06-03 | 1996-06-03 | |
US08/657,147 | 1996-06-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997027559A1 true WO1997027559A1 (en) | 1997-07-31 |
Family
ID=27081378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/001491 WO1997027559A1 (en) | 1996-01-26 | 1997-01-27 | Method of creating and searching a molecular virtual library using validated molecular structure descriptors |
Country Status (5)
Country | Link |
---|---|
US (3) | US6240374B1 (en) |
EP (1) | EP0892963A1 (en) |
AU (1) | AU1847997A (en) |
CA (1) | CA2245935C (en) |
WO (1) | WO1997027559A1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999023587A2 (en) * | 1997-11-04 | 1999-05-14 | Cerep | Method of virtual retrieval of analogs of lead compounds |
WO1999035598A1 (en) * | 1997-12-30 | 1999-07-15 | Synt:Em (S.A.) | Method for providing, identifying and describing molecules capable of having a required activity, in particular in pharmacology and molecules resulting from said method |
WO1999035599A1 (en) * | 1998-01-09 | 1999-07-15 | Everett, Richard, Stephen, Hans | Apparatus and method for use in the manufacture of chemical compounds |
WO1999050770A1 (en) * | 1998-03-27 | 1999-10-07 | Combichem, Inc. | Method and system for search of implicitly described virtual libraries |
WO2000033218A1 (en) * | 1998-11-27 | 2000-06-08 | Astrazeneca Ab | A global method for mapping property spaces |
EP1057014A1 (en) * | 1998-02-26 | 2000-12-06 | Openeye Scientific, Inc. | Method and apparatus for evaluating molecular similarity |
EP1077993A1 (en) * | 1998-05-12 | 2001-02-28 | Isis Pharmaceuticals, Inc. | Generation of combinatorial libraries of compounds corresponding to virtual libraries of compounds |
EP1127312A1 (en) * | 1998-05-12 | 2001-08-29 | Isis Pharmaceuticals, Inc. | Generation of virtual combinatorial libraries of compounds |
US6295514B1 (en) | 1996-11-04 | 2001-09-25 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for representing similarity/dissimilarity between chemical compounds |
WO2001086572A1 (en) * | 2000-05-08 | 2001-11-15 | Personal Chemistry I Uppsala Ab | Method for performing multiple chemical reactions and a kit and system therefor |
US6434490B1 (en) | 1994-09-16 | 2002-08-13 | 3-Dimensional Pharmaceuticals, Inc. | Method of generating chemical compounds having desired properties |
US6453246B1 (en) | 1996-11-04 | 2002-09-17 | 3-Dimensional Pharmaceuticals, Inc. | System, method, and computer program product for representing proximity data in a multi-dimensional space |
US6571227B1 (en) | 1996-11-04 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Method, system and computer program product for non-linear mapping of multi-dimensional data |
US6671627B2 (en) | 2000-02-29 | 2003-12-30 | 3-D Pharmaceuticals, Inc. | Method and computer program product for designing combinatorial arrays |
US6678619B2 (en) | 2000-09-20 | 2004-01-13 | Victor S. Lobanov | Method, system, and computer program product for encoding and building products of a virtual combinatorial library |
US6834239B2 (en) | 2000-08-22 | 2004-12-21 | Victor S. Lobanov | Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks |
US6907350B2 (en) * | 2000-03-13 | 2005-06-14 | Chugai Seiyaku Kabushiki Kaisha | Method, system and apparatus for handling information on chemical substances |
US7039621B2 (en) | 2000-03-22 | 2006-05-02 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method, and computer program product for representing object relationships in a multidimensional space |
US7054757B2 (en) | 2001-01-29 | 2006-05-30 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Method, system, and computer program product for analyzing combinatorial libraries |
US7110888B1 (en) | 1998-02-26 | 2006-09-19 | Openeye Scientific Software, Inc. | Method for determining a shape space for a set of molecules using minimal metric distances |
US7139739B2 (en) | 2000-04-03 | 2006-11-21 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Method, system, and computer program product for representing object relationships in a multidimensional space |
US7416524B1 (en) | 2000-02-18 | 2008-08-26 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method and computer program product for fast and efficient searching of large chemical libraries |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6185506B1 (en) * | 1996-01-26 | 2001-02-06 | Tripos, Inc. | Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors |
US7912689B1 (en) | 1999-02-11 | 2011-03-22 | Cambridgesoft Corporation | Enhancing structure diagram generation through use of symmetry |
US7295931B1 (en) * | 1999-02-18 | 2007-11-13 | Cambridgesoft Corporation | Deriving fixed bond information |
US6721754B1 (en) * | 1999-04-28 | 2004-04-13 | Arena Pharmaceuticals, Inc. | System and method for database similarity join |
US6850876B1 (en) * | 1999-05-04 | 2005-02-01 | Smithkline Beecham Corporation | Cell based binning methods and cell coverage system for molecule selection |
US7742877B1 (en) * | 1999-07-22 | 2010-06-22 | Becton, Dickinson & Company | Methods, apparatus and computer program products for formulating culture media |
DE10004468A1 (en) * | 2000-02-02 | 2001-08-23 | Inst Pflanzenbiochemie Ipb | Allen oxide cyclase gene and its use for the preparation of jasmonic acid |
US20020077757A1 (en) * | 2000-04-03 | 2002-06-20 | Libraria, Inc. | Chemistry resource database |
US7082430B1 (en) * | 2000-04-17 | 2006-07-25 | Accenture Llp | Collaboration planning in a collaborative work tool architecture |
US7171448B1 (en) | 2000-04-17 | 2007-01-30 | Accenture Ans | Conducting activities in a collaborative work tool architecture |
US7272509B1 (en) * | 2000-05-05 | 2007-09-18 | Cambridgesoft Corporation | Managing product information |
US7356419B1 (en) | 2000-05-05 | 2008-04-08 | Cambridgesoft Corporation | Deriving product information |
US20020025535A1 (en) * | 2000-06-15 | 2002-02-28 | Diller David J. | Prioritization of combinatorial library screening |
US6971059B1 (en) * | 2000-11-28 | 2005-11-29 | Agilent Technologies, Inc. | Chromatographic or spectroscopic reports with hyperlinks to allow direct access to external references |
US20030087334A1 (en) * | 2001-04-02 | 2003-05-08 | Libraria, Inc. | Method of flexibly generating diverse reaction chemistries |
US7330793B2 (en) * | 2001-04-02 | 2008-02-12 | Cramer Richard D | Method for searching heterogeneous compound databases using topomeric shape descriptors and pharmacophoric features |
US7158888B2 (en) * | 2001-05-04 | 2007-01-02 | Takeda San Diego, Inc. | Determining structures by performing comparisons between molecular replacement results for multiple different biomolecules |
US6694330B2 (en) | 2001-05-09 | 2004-02-17 | Row 2 Technologies, Inc. | System and method for identifying the raw materials consumed in the manufacture of a chemical product |
WO2003019183A1 (en) * | 2001-08-23 | 2003-03-06 | Deltagen Research Laboratories, L.L.C. | Process for the informative and iterative design of a gene-family screening library |
AU2002357653A1 (en) * | 2001-10-11 | 2003-04-22 | Emerald Biostructures, Inc. | Method and a system for automating the execution of amore over a heterogenous network of computers |
EP1302866A1 (en) * | 2001-10-15 | 2003-04-16 | Cerep SA | Method of predicting biological activity profiles based on the neighborhood behavior of "in silico" similarity metrics calibrated with respect to activity spaces |
DE10159262B4 (en) * | 2001-12-03 | 2007-12-13 | Siemens Ag | Identify pharmaceutical targets |
US7329222B2 (en) * | 2002-02-25 | 2008-02-12 | Tripos, L.P. | Comparative field analysis (CoMFA) utilizing topomeric alignment of molecular fragments |
WO2003088090A2 (en) * | 2002-04-10 | 2003-10-23 | Transtech Pharma, Inc. | System and method for data analysis, manipulation, and visualization |
WO2003107120A2 (en) * | 2002-06-13 | 2003-12-24 | 3-Dimensional Pharmaceuticals, Inc. | Methods, systems, and computer program products for representing object relationships in a multidimensional space |
GB2391431A (en) * | 2002-07-30 | 2004-02-04 | Fujitsu Ltd | Adaptive modulation and coding method |
US7505952B1 (en) * | 2003-10-20 | 2009-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Statistical inference of static analysis rules |
EP1721268A1 (en) * | 2004-03-05 | 2006-11-15 | Applied Research Systems ARS Holding N.V. | Method for fast substructure searching in non-enumerated chemical libraries |
EP1628234A1 (en) * | 2004-06-07 | 2006-02-22 | Universita' Degli Studi di Milano-Bicocca | Method of construction and selection of virtual libraries in combinatorial chemistry |
US20060052943A1 (en) * | 2004-07-28 | 2006-03-09 | Karthik Ramani | Architectures, queries, data stores, and interfaces for proteins and drug molecules |
EP1807783A4 (en) * | 2004-08-19 | 2009-01-28 | Biogen Idec Inc | Methods for describing a group of chemical structures |
JP2006309446A (en) * | 2005-04-27 | 2006-11-09 | Toshiba Corp | Classification dictionary updating device, classification dictionary updating program, and classification dictionary updating method |
EP1762954B1 (en) * | 2005-08-01 | 2019-08-21 | F.Hoffmann-La Roche Ag | Automated generation of multi-dimensional structure activity and structure property relationships |
US7860657B2 (en) * | 2006-03-24 | 2010-12-28 | Cramer Richard D | Forward synthetic synthon generation and its useto identify molecules similar in 3 dimensional shape to pharmaceutical lead compounds |
JP5239367B2 (en) * | 2007-03-19 | 2013-07-17 | 富士通株式会社 | Information providing system, information providing program, and information providing method |
JP5052985B2 (en) * | 2007-07-31 | 2012-10-17 | 住友重機械工業株式会社 | Molecular simulation method, molecular simulation apparatus, molecular simulation program, and recording medium recording the program |
US20090228463A1 (en) * | 2008-03-10 | 2009-09-10 | Cramer Richard D | Method for Searching Compound Databases Using Topomeric Shape Descriptors and Pharmacophoric Features Identified by a Comparative Molecular Field Analysis (CoMFA) Utilizing Topomeric Alignment of Molecular Fragments |
CN102282560B (en) * | 2008-12-05 | 2015-08-19 | 狄克雷佩特公司 | For generation of the method for the virtual compound chained library in Markush structure Patent right requirement |
WO2010020892A2 (en) * | 2009-07-07 | 2010-02-25 | The Procter & Gamble Company | Property-space similarity modeling |
WO2012031215A1 (en) * | 2010-09-03 | 2012-03-08 | University Of Louisville Research Foundation, Inc. | Hybird fragment-ligand modeling for classifying chemical compounds |
WO2012139421A1 (en) * | 2011-04-11 | 2012-10-18 | Yan Jingbo | Uses of multi-dimensional matrix in pharmaceutical molecule design and pharmaceutical molecule design method |
US8799223B1 (en) * | 2011-05-02 | 2014-08-05 | Symantec Corporation | Techniques for data backup management |
US9218460B2 (en) * | 2011-05-09 | 2015-12-22 | The Regents Of The University Of California | Defining and mining a joint pharmacophoric space through geometric features |
US20120303422A1 (en) * | 2011-05-27 | 2012-11-29 | Diran Li | Computer-Implemented Systems And Methods For Ranking Results Based On Voting And Filtering |
JP6400037B2 (en) * | 2016-03-17 | 2018-10-03 | ヤフー株式会社 | Determination apparatus and determination method |
WO2020023650A1 (en) * | 2018-07-25 | 2020-01-30 | Wuxi Nextcode Genomics Usa, Inc. | Retrosynthesis prediction using deep highway networks and multiscale reaction classification |
US11735292B2 (en) | 2018-08-07 | 2023-08-22 | International Business Machines Corporation | Intelligent personalized chemical synthesis planning |
JP7347147B2 (en) * | 2019-11-18 | 2023-09-20 | 株式会社レゾナック | Molecular descriptor generation system, molecular descriptor generation method, and molecular descriptor generation program |
CN111354424B (en) * | 2020-02-27 | 2023-06-23 | 北京晶泰科技有限公司 | Prediction method and device for potential active molecules and computing equipment |
JP2024139949A (en) * | 2023-03-28 | 2024-10-10 | 富士通株式会社 | EVALUATION PROGRAM, EVALUATION APPARATUS, AND EVALUATION METHOD |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025388A (en) * | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5345516A (en) * | 1991-04-19 | 1994-09-06 | International Business Machines Corporation | Apparatus and method for parsing a chemical string |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642762A (en) | 1984-05-25 | 1987-02-10 | American Chemical Society | Storage and retrieval of generic chemical structure representations |
JPS61223941A (en) | 1985-03-29 | 1986-10-04 | Kagaku Joho Kyokai | Method for storing and retrieving chemical structure |
JPS6257017A (en) | 1985-09-05 | 1987-03-12 | Fuji Photo Film Co Ltd | Processing method for chemical reaction information |
WO1990007329A1 (en) | 1989-01-06 | 1990-07-12 | The Regents Of The University Of California | Selection method for pharmacologically active compounds |
EP0496902A1 (en) | 1991-01-26 | 1992-08-05 | International Business Machines Corporation | Knowledge-based molecular retrieval system and method |
US5157736A (en) | 1991-04-19 | 1992-10-20 | International Business Machines Corporation | Apparatus and method for optical recognition of chemical graphics |
US5386507A (en) | 1991-07-18 | 1995-01-31 | Teig; Steven L. | Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof |
US5424963A (en) | 1992-11-25 | 1995-06-13 | Photon Research Associates, Inc. | Molecular dynamics simulation method and apparatus |
US6081766A (en) | 1993-05-21 | 2000-06-27 | Axys Pharmaceuticals, Inc. | Machine-learning approach to modeling biological activity for molecular design and to modeling other characteristics |
US5703792A (en) * | 1993-05-21 | 1997-12-30 | Arris Pharmaceutical Corporation | Three dimensional measurement of molecular diversity |
US5434796A (en) | 1993-06-30 | 1995-07-18 | Daylight Chemical Information Systems, Inc. | Method and apparatus for designing molecules with desired properties by evolving successive populations |
US5583973A (en) | 1993-09-17 | 1996-12-10 | Trustees Of Boston University | Molecular modeling method and system |
US5619421A (en) | 1994-06-17 | 1997-04-08 | Massachusetts Institute Of Technology | Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure |
US5577239A (en) | 1994-08-10 | 1996-11-19 | Moore; Jeffrey | Chemical structure storage, searching and retrieval system |
US5647036A (en) | 1994-09-09 | 1997-07-08 | Deacon Research | Projection display with electrically-controlled waveguide routing |
US5463564A (en) | 1994-09-16 | 1995-10-31 | 3-Dimensional Pharmaceuticals, Inc. | System and method of automatically generating chemical compounds with desired properties |
US5806062A (en) * | 1995-10-17 | 1998-09-08 | Lucent Technologies Inc. | Data analysis system using virtual databases |
US5752019A (en) | 1995-12-22 | 1998-05-12 | International Business Machines Corporation | System and method for confirmationally-flexible molecular identification |
US5880972A (en) * | 1996-02-26 | 1999-03-09 | Pharmacopeia, Inc. | Method and apparatus for generating and representing combinatorial chemistry libraries |
US6253168B1 (en) * | 1998-05-12 | 2001-06-26 | Isis Pharmaceuticals, Inc. | Generation of virtual combinatorial libraries of compounds |
-
1997
- 1997-01-27 AU AU18479/97A patent/AU1847997A/en not_active Abandoned
- 1997-01-27 EP EP97904095A patent/EP0892963A1/en not_active Withdrawn
- 1997-01-27 WO PCT/US1997/001491 patent/WO1997027559A1/en not_active Application Discontinuation
- 1997-01-27 CA CA002245935A patent/CA2245935C/en not_active Expired - Lifetime
- 1997-07-20 US US08/903,217 patent/US6240374B1/en not_active Expired - Lifetime
-
2001
- 2001-05-25 US US09/866,495 patent/US20020099525A1/en not_active Abandoned
- 2001-05-25 US US09/866,543 patent/US7136758B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025388A (en) * | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5307287A (en) * | 1988-08-26 | 1994-04-26 | Tripos Associates, Inc. | Comparative molecular field analysis (COMFA) |
US5345516A (en) * | 1991-04-19 | 1994-09-06 | International Business Machines Corporation | Apparatus and method for parsing a chemical string |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6434490B1 (en) | 1994-09-16 | 2002-08-13 | 3-Dimensional Pharmaceuticals, Inc. | Method of generating chemical compounds having desired properties |
US7188055B2 (en) | 1996-11-04 | 2007-03-06 | Johnson & Johnson Pharmaceutical Research, & Development, L.L.C. | Method, system, and computer program for displaying chemical data |
US6571227B1 (en) | 1996-11-04 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Method, system and computer program product for non-linear mapping of multi-dimensional data |
US6453246B1 (en) | 1996-11-04 | 2002-09-17 | 3-Dimensional Pharmaceuticals, Inc. | System, method, and computer program product for representing proximity data in a multi-dimensional space |
US7117187B2 (en) | 1996-11-04 | 2006-10-03 | Johnson & Johnson Pharmaceutical Reseach & Develpment, L.L.C. | Method, system and computer program product for non-linear mapping of multi-dimensional data |
US6295514B1 (en) | 1996-11-04 | 2001-09-25 | 3-Dimensional Pharmaceuticals, Inc. | Method, system, and computer program product for representing similarity/dissimilarity between chemical compounds |
WO1999023587A2 (en) * | 1997-11-04 | 1999-05-14 | Cerep | Method of virtual retrieval of analogs of lead compounds |
WO1999023587A3 (en) * | 1997-11-04 | 1999-07-29 | Cerep | Method of virtual retrieval of analogs of lead compounds |
AU771430B2 (en) * | 1997-12-30 | 2004-03-25 | Synt:Em (S.A.) | Method for providing, identifying and describing molecules capable of having a required activity, in particular in pharmacology and molecules resulting from said method |
WO1999035598A1 (en) * | 1997-12-30 | 1999-07-15 | Synt:Em (S.A.) | Method for providing, identifying and describing molecules capable of having a required activity, in particular in pharmacology and molecules resulting from said method |
US7024311B1 (en) | 1997-12-30 | 2006-04-04 | Synt:Em S.A. | Computer-aided method for the provision, identification and description of molecules capable of exhibiting a desired behavior, more particularly in the pharmaceutical sector, and molecules obtained by said method |
WO1999035599A1 (en) * | 1998-01-09 | 1999-07-15 | Everett, Richard, Stephen, Hans | Apparatus and method for use in the manufacture of chemical compounds |
EP1057014A1 (en) * | 1998-02-26 | 2000-12-06 | Openeye Scientific, Inc. | Method and apparatus for evaluating molecular similarity |
US8165818B2 (en) | 1998-02-26 | 2012-04-24 | Openeye Scientific Software, Inc. | Method and apparatus for searching molecular structure databases |
US7110888B1 (en) | 1998-02-26 | 2006-09-19 | Openeye Scientific Software, Inc. | Method for determining a shape space for a set of molecules using minimal metric distances |
EP1057014A4 (en) * | 1998-02-26 | 2006-01-25 | Openeye Scient Software Inc | Method and apparatus for evaluating molecular similarity |
WO1999050770A1 (en) * | 1998-03-27 | 1999-10-07 | Combichem, Inc. | Method and system for search of implicitly described virtual libraries |
EP1127312A1 (en) * | 1998-05-12 | 2001-08-29 | Isis Pharmaceuticals, Inc. | Generation of virtual combinatorial libraries of compounds |
EP1077993A1 (en) * | 1998-05-12 | 2001-02-28 | Isis Pharmaceuticals, Inc. | Generation of combinatorial libraries of compounds corresponding to virtual libraries of compounds |
EP1127312A4 (en) * | 1998-05-12 | 2004-09-08 | Isis Pharmaceuticals Inc | Generation of virtual combinatorial libraries of compounds |
EP1077993A4 (en) * | 1998-05-12 | 2004-09-08 | Isis Pharmaceuticals Inc | Generation of combinatorial libraries of compounds corresponding to virtual libraries of compounds |
WO2000033218A1 (en) * | 1998-11-27 | 2000-06-08 | Astrazeneca Ab | A global method for mapping property spaces |
US6675136B1 (en) | 1998-11-27 | 2004-01-06 | Astrazeneca Ab | Global method for mapping property spaces |
AU764991B2 (en) * | 1998-11-27 | 2003-09-04 | Astrazeneca Ab | A global method for mapping property spaces |
US7416524B1 (en) | 2000-02-18 | 2008-08-26 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method and computer program product for fast and efficient searching of large chemical libraries |
US6671627B2 (en) | 2000-02-29 | 2003-12-30 | 3-D Pharmaceuticals, Inc. | Method and computer program product for designing combinatorial arrays |
US6907350B2 (en) * | 2000-03-13 | 2005-06-14 | Chugai Seiyaku Kabushiki Kaisha | Method, system and apparatus for handling information on chemical substances |
US7039621B2 (en) | 2000-03-22 | 2006-05-02 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | System, method, and computer program product for representing object relationships in a multidimensional space |
US7139739B2 (en) | 2000-04-03 | 2006-11-21 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Method, system, and computer program product for representing object relationships in a multidimensional space |
WO2001086572A1 (en) * | 2000-05-08 | 2001-11-15 | Personal Chemistry I Uppsala Ab | Method for performing multiple chemical reactions and a kit and system therefor |
US7112450B2 (en) | 2000-05-08 | 2006-09-26 | Personal Chemistry I Uppsala Ab | Method for performing multiple chemical reactions and a kit and system therefor |
US6834239B2 (en) | 2000-08-22 | 2004-12-21 | Victor S. Lobanov | Method, system, and computer program product for determining properties of combinatorial library products from features of library building blocks |
US6678619B2 (en) | 2000-09-20 | 2004-01-13 | Victor S. Lobanov | Method, system, and computer program product for encoding and building products of a virtual combinatorial library |
US7054757B2 (en) | 2001-01-29 | 2006-05-30 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Method, system, and computer program product for analyzing combinatorial libraries |
Also Published As
Publication number | Publication date |
---|---|
AU1847997A (en) | 1997-08-20 |
CA2245935C (en) | 2004-07-20 |
US20020099525A1 (en) | 2002-07-25 |
US20020099526A1 (en) | 2002-07-25 |
CA2245935A1 (en) | 1997-07-31 |
US7136758B2 (en) | 2006-11-14 |
US6240374B1 (en) | 2001-05-29 |
EP0892963A1 (en) | 1999-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6240374B1 (en) | Further method of creating and rapidly searching a virtual library of potential molecules using validated molecular structural descriptors | |
US6185506B1 (en) | Method for selecting an optimally diverse library of small molecules based on validated molecular structural descriptors | |
US7765070B2 (en) | Ellipsoidal gaussian representations of molecules and molecular fields | |
US20070016377A1 (en) | System and method for improved computer drug design | |
US7860657B2 (en) | Forward synthetic synthon generation and its useto identify molecules similar in 3 dimensional shape to pharmaceutical lead compounds | |
Poirrette et al. | Comparison of protein surfaces using a genetic algorithm | |
CA2346235A1 (en) | Pharmacophore fingerprinting in qsar and primary library design | |
Martin et al. | Does Combinatorial Chemistry Obviate Computer‐Aided Drug Design? | |
US6675103B1 (en) | Visualizing high dimensional descriptors of molecular structures | |
US20060178840A1 (en) | Method and apparatus for searching molecular structure databases | |
US7330793B2 (en) | Method for searching heterogeneous compound databases using topomeric shape descriptors and pharmacophoric features | |
Humblet et al. | 3D Database searching and docking strategles | |
CA2477459C (en) | Comparative field analysis (comfa) utilizing topomeric alignment of molecular fragments | |
EP1468392B1 (en) | Method for binding site identification using a multi-scale approach | |
EP1203330A2 (en) | Analyzing molecule and protein diversity | |
Pitman | Fragment assembly in the automated molecular invention system: INVENTON | |
Maiocchi | Genetic algorithms in molecular modelling: a review | |
Wei et al. | Statistical analysis of protein structures | |
Sun | Detecting multiple protein folding trajectories and structural alignment | |
Meek et al. | Computer Techniques: Identifying Similarities Between Small Molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN CZ HU IL JP KR NO PL US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2245935 Country of ref document: CA Ref country code: CA Ref document number: 2245935 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997904095 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97527113 Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 1997904095 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997904095 Country of ref document: EP |